WO2000051672A1 - Nasal delivery device - Google Patents
Nasal delivery device Download PDFInfo
- Publication number
- WO2000051672A1 WO2000051672A1 PCT/IB2000/000273 IB0000273W WO0051672A1 WO 2000051672 A1 WO2000051672 A1 WO 2000051672A1 IB 0000273 W IB0000273 W IB 0000273W WO 0051672 A1 WO0051672 A1 WO 0051672A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- flow
- nasal
- substance
- delivery device
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
- A61M15/0098—Activated by exhalation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0866—Passive resistors therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0233—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
- A61M16/1055—Filters bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
- A61M16/106—Filters in a path
- A61M16/1065—Filters in a path in the expiratory path
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/43—General characteristics of the apparatus making noise when used correctly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/59—Aesthetic features, e.g. distraction means to prevent fears of child patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0618—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0202—Enemata; Irrigators with electronic control means or interfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0279—Cannula; Nozzles; Tips; their connection means
Definitions
- the present invention relates to a delivery device for and a method of delivering a substance, in particular one of a liquid, as a suspension or solution, or a powder containing a medicament, especially a topical pharmaceutical, a cleansing agent, or an irrigating agent, as a liquid, preferably combined with a cleansing agent, to the nasal airway of a subject.
- the present invention relates to the delivery of medicament to and the irrigation of the nasal mucosa, the anterior region of nasopharynx, the paranasal sinus ostia, the tubal ostia of the auditory tubes, the sinus tubes, the auditory tubes, the tympanic cavities and the paranasal sinuses.
- the nasal airway 1 comprises the two nasal cavities separated by the nasal septum, which airway 1 includes numerous ostia, such as the paranasal sinus ostia 3 and the tubal ostia 5, olfactory cells and is lined by the nasal mucosa.
- the nasal airway 1 can communicate with the nasopharynx 7, the oral cavity 9 and the lower airway 11, with the nasal airway 1 being in selective communication with the anterior region of the nasopharynx 7 and the oral cavity 9 by opening and closing of the oropharyngeal velum 13.
- the velum 13, which is often referred to as the soft palate, is illustrated in solid line in the closed position, as achieved by providing a certain positive pressure in the oral cavity 9, such as achieved on exhalation through the oral cavity 9, and in dashed line in the open position.
- nasal inflammation specifically rhinitis
- allergic and non-allergic inflammation of the nasal airway can typically effect between 10 and 20 % of the population, with nasal congestion of the erectile tissues of the nasal concha, lacrimation, secretion of watery mucus, sneezing and itching being the most common symptoms.
- nasal congestion impedes nasal breathing and promotes oral breathing, leading to snoring and sleep disturbance.
- Other nasal conditions include nasal polyps which arise from the paranasal sinuses, hypertrophic adenoids, secretory otitis media, sinus disease and reduced olfaction.
- topical administration of medicaments is preferable, particularly where the nasal mucosa is the prime pathological pathway, such as in treating or relieving nasal congestion.
- topical administration is advantageous in minimising the possible side effects of systemic administration.
- Medicaments that are commonly topically delivered include decongestants, anti- histamines, cromoglycates, steroids and antibiotics.
- topical steroids have been shown to have an effect on nasal congestion.
- Topical decongestants have also been suggested for use in relieving nasal congestion.
- topical administration of pharmaceuticals has been used to treat or at least relieve symptoms of inflammation in the anterior region of the nasopharynx, the paranasal sinuses and the auditory tubes.
- liquids in particular saline solutions
- saline solutions are commonly practised to remove particles and secretions, as well as to improve the mucociliary activity of the nasal mucosa.
- medicaments are now increasingly systemically delivered through the nasal pathway, the nasal pathway offering a good administration route for the systemic delivery of pharmaceuticals, such as hormones, for example oxytocin, and anti- migraine compositions, as the high blood flow and large surface area of the nasal mucosa advantageously provides for rapid systemic uptake.
- pharmaceuticals such as hormones, for example oxytocin, and anti- migraine compositions
- a variety of delivery systems have been developed to deliver substances to the nasal airways of subjects.
- spray bottles have been used to deliver a medicament-containing liquid or an irrigating liquid to the nasal airways of subjects.
- the distribution of the delivered substance, in particular to the posterior region of the nasal airway is less than ideal, especially in the cases of moderate and severe nasal obstruction. This poor distribution is often further exacerbated by a subject inhaling through the nasal airway during delivery, as is often prescribed, in an attempt to deliver the substance to the posterior region of the nasal airway.
- an amount of the substance can be drawn into the lungs or swallowed in each delivery, which could be problematic in paediatric subjects if the medicament is a potent pharmaceutical, such as a steroid, which has to be administered frequently.
- the spray is frequently directed against the nasal septum which can undesirably lead to localised deposition. Further, the mechanical action of the delivery mechanism of the spray bottles can cause irritation and bleeding.
- GB-A-408856 discloses a delivery device, which in one mode of use, apparently allows for the delivery of two separate air flows entraining medicament into respective ones of the nasal cavities of a subject.
- This delivery device comprises a chamber containing a sponge saturated with medicament, a mouthpiece connected to the chamber and first and second nosepieces connected to the chamber.
- the mouthpiece is taken in the mouth of a subject and the nosepieces fitted into respective ones of the nostrils of the subject, and on exhalation through the mouthpiece separate air flows entraining medicament are apparently driven into the nasal cavities of the subject.
- WO-A-98/53869 discloses a delivery device for delivering a powder containing a medicament to the nasal mucosa in one of the nasal cavities of a subject.
- This device comprises a tubular section which contains a metered dose of powdered medicament.
- the ends of the tubular section are respectively located in the nostril of one of the nasal cavities and the mouth of a subject, and on exhalation by the subject through his or her mouth the exhaled air entrains the powdered medicament and delivers the same into the one nasal cavity, with the exhaled air backflowing out of the one nostril around the tubular section.
- the tubular section includes a flexible portion upstream of the dose of powdered medicament.
- this flexible portion allows the subject to close the tubular section at a point upstream of the medicament, such that, on release of the closed flexible portion during exhalation, a short explosive air flow entraining medicament is delivered into the one nasal cavity.
- the end of the tubular section located in the nostril can be shaped to act to locate the tubular section in a position in the nostril which allows for the deposition of the powdered medicament on the nasal mucosa.
- this delivery device Whilst this delivery device is simple in construction, the operation of the device still does not provide for the effective delivery of substances, in particular one of a liquid or powder containing medicament, to the posterior region of the nasal airway, since medicament is delivered separately to each of the nasal cavities and the air flow into and out of each nasal cavity is through the same opening, namely the respective nostril, with the closed posterior region of the respective nasal cavity acting as a pressure reflecting surface which causes the exhaled air to backflow out of the one nostril before ever adequately reaching the posterior region of the respective nasal cavity. Further, in providing a short explosive burst of air flow into one of the nasal cavities, it is not possible to achieve a sustained and controlled bi-directional air flow through the nasal cavities which has been found necessary to deliver a substance effectively to the posterior region of the nasal airway.
- the present invention provides a delivery device for delivering a substance to the nasal airway of a subject, comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril.
- the substance comprises a dry powder.
- the substance comprises liquid droplets.
- the particle size distribution of the substance is principally in the range of about 1 to 10 ⁇ m.
- the substance contains a medicament, particularly for the treatment of a nasal condition.
- the particle size distribution of the substance can include a smaller fraction of larger particles, typically in the range of about 10 to 30 ⁇ m, and preferably in the range of about 20 to 30 ⁇ m.
- the substance can be a cleansing agent, as a powder or liquid, for cleansing the nasal airway, or a liquid, which may preferably contain a cleansing agent, for irrigating the nasal airway.
- the delivery device could be used to administer saline or other solutions to the nasal airway to remove particles and secretions, in particular from the posterior region of the nasal airway, which resulting solution could be analysed for diagnostic or research purposes.
- the particle size distribution of the cleansing or irrigating agents can include a fraction of larger particles, particularly in relation to the mechanical action of the particles.
- the present invention also provides a method of delivering a substance to the nasal airway of a subject, comprising the steps of: sealing one of the nostrils of a subject to an outlet of a delivery unit such as to prevent the escape of a gas flow through the one nostril; closing the oropharyngeal velum of the subject; and delivering a gas flow entraining a substance through the outlet at such a pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject.
- the closure of the velum is achieved directly by the use of an instrument for pressing against the velum to close the same or a bung for temporarily closing the opening behind the velum between the nasal airway and the oral cavity.
- the closure of the velum is achieved indirectly by the creation of a positive pressure in the oral cavity, or more correctly a positive pressure differential between the oral cavity and the nasal airway, such as achieved on exhalation.
- the velum is closed simultaneously with the onset of the delivery of the substance to the nasal airway.
- closure of the velum is achieved automatically by the subject exhaling against a flow resistor, which flow resistor may be operably connected to a tubular section held between the lips of the subject.
- the flow resistor can be configured to provide the required intra-oral positive pressure.
- the air flow of exhalation by a subject is used to power a mechanism which disperses the substance into a volume of air and delivers that dispersed substance into the nasal airway.
- the mechanism is so arranged that the substance is delivered into the nasal airway after the velum has been closed or simultaneously with velum closure.
- the substance is delivered into the nasal airway after the velum has been closed or simultaneously with velum closure.
- bi-directional flow through the nasal cavities is possible only when the velum is closed and that any substance delivered prior to closure of the velum would undesirably be delivered to the lower airway or the gut.
- the release of the substance into the nasal airway is triggered by the air flow created on exhalation.
- a pressure-sensitive valve is utilised to trigger release of the substance when a predetermined flow rate has been developed. It should be understood that control of the flow rate of the gas in which the substance is delivered is important, as this flow rate, along with the particle size distribution of the substance, are the significant factors determining the particle deposition efficiency.
- the pressure-sensitive valve is not opened until the subject has maintained a predetermined flow rate, and can be closed when the flow rate drops below the predetermined flow rate so as to stop the delivery of the substance.
- one or both of the timing and duration of the opening of the pressure-sensitive valve and the dose released are carefully controlled to ensure a standardised dosage.
- the exhalation flow is provided to induce the mixing of a metered dose of the substance
- the delivery of the gas flow can be prolonged to flush the nasal airway as this prolonged flushing does not effect the delivered dose.
- a mechanical device powered by a hand-chargeable spring, pressurised air or similar, may be used to provide the driving gas.
- the flow characteristics can be optimised to improve the deposition of the substance and the comfort factor, such as to avoid an abrupt onset which is likely to induce withdrawal reflexes.
- a metered dose of the substance is dispensed into a delivery chamber by a dosing mechanism.
- This dosing mechanism can be constructed in such a way as to allow for a gradual release of the substance. This gradual release will better enable the substance to be entrained by the gas flow and thereby improve delivery to all ventilated parts of the nasal airway, in particular in the contralateral nasal cavity.
- the exhalation air flow developed by the subject which closes the velum, provides the gas flow for entraining the substance and providing the bi-directional flow. This configuration is advantageous in that a separate driving gas flow need not be developed.
- the nosepiece is configured to extend about 1 cm into the one nasal cavity so as to expand the valve region, a region located about 2 to 3 cm within a nasal cavity which is usually the flow limiting region, and reduce the resistance which may be high in the case of nasal inflammation.
- the shape of the nosepiece can be tailored to suit specific needs.
- the internal shape of the nosepiece may be optimised to promote turbulence and achieve a more optimal dispersion of the substance.
- the nosepiece may include a tight fitting nasal olive, which can aid the creation of a suitable physiological gas flow.
- the olive may be detachable such as to allow for other olives of the same or different dimensions to be fitted.
- a nasal olive can be introduced into the other nostril to reduce resistance and facilitate flow therethrough.
- the delivery device can include an indicator for indicating the magnitude of the gas flow.
- a filter can be employed if high humidity represents a problem for administration of the solid.
- the substance can be a single compound or a mixture of compounds, which compounds can be in any suitable form, such as a powder form, a solution, or a suspension.
- the substance can be any suitable substance for delivery to a human or in some cases an animal.
- the substance may be for delivery for action in any part of the nasal airway, or in any of the surrounding tissues or organs. Also, the substance may be for delivery for action in a region remote from the nasal airway.
- the substance is for delivery for subsequent action in any part of the nasal airway, or in any of the surrounding tissues or organs.
- the substance may have a beneficial medical effect, which can include a diagnostic effect, a therapeutic effect, a prophylactic effect, and a cleansing effect such as the removal of particles, crusts, secretions, debris, etc.
- a beneficial medical effect which can include a diagnostic effect, a therapeutic effect, a prophylactic effect, and a cleansing effect such as the removal of particles, crusts, secretions, debris, etc.
- the substance has a therapeutic effect.
- the substance is a pharmaceutical.
- the pharmaceutical can be admixed with any suitable carrier, diluent, excipient or adjuvant.
- the pharmaceutical is for the treatment of any one or more of the above- mentioned conditions.
- the pharmaceutical may be for the treatment of any allergic and non-allergic inflammatory disease.
- Typical pharmaceuticals for administration include, but are not limited to, steroids, anti-histamines, cromoglycates, anti-allergic pharmaceuticals, anti-inflammatory pharmaceuticals, anti-leucotriens, lactation promoters such as oxytocin, and anti- migraine pharmaceuticals.
- the delivery device of the present invention improves the effect of topical pharmaceuticals in the treatment of upper airway pathologies, such as hypertrophic adenoids and chronic sectretory otitis media.
- the device can also be used to irrigate or cleanse the nasal airway with saline or other solutions, preferably containing oils or herbs.
- the device of the present invention can be tailored to suit particular needs.
- balloons or pop-up figures can easily be integrated to provide a semi- quantitaive indication of the flow rate and to improve the acceptability and ease of administration in small children.
- the delivery device may also be used as a nasal lavage means in the collection of mediators and cells that originate from the nasal mucosa for, for example, diagnostic analysis or research purposes.
- the mediators and cells can be expelled into a suitable collecting vessel after the nasal airway has been exposed to a suitable solution, such as a saline solution, for a sufficient period of time to ensure sufficient transfer of the mediators and cells into the solution.
- a suitable solution such as a saline solution
- This use of the device may require the use of a gas flow separate to the exhaled air flow as the flow used to flush the nasal airway.
- use of the exhaled air may not be possible as the lower airways may contain mediators, secretions and cells originating from the lower airways which would contaminate the nasal sample.
- the fluid escaping from the outlet nostril may be collected in a vessel.
- the fluid escaping from the outlet nostril may be absorbed onto a filter for direct or delayed analysis.
- filters and the like may even yield an almost immediate detection result of certain organisms, such as bacteria, viruses or mediators.
- the delivery device of the present invention is advantageous for a number of reasons.
- the delivery device provides a very simple and efficient means of delivering substances, such as pharmaceuticals, saline solutions, etc, into the nasal airway.
- substances such as pharmaceuticals, saline solutions, etc
- the device utilises very simple technology with few movable parts, making the device relatively inexpensive to mass produce.
- the device of the present invention can be made in a disposable form, thus avoiding the need for the delivered substance to include any preservatives.
- the present invention also eliminates the need for the subsequent flushing or spraying methods that are associated with some of the prior art devices. However, for some applications it may still be desirable to perform a subsequent flushing or spraying operation.
- the delivery device of the present invention is advantageous as, in use, the tight seal between the nosepiece and the one nostril ensures a prolonged penetration of the complex nasal airway, a bi-directional gas flow through the nasal cavities and deposition of the substance in the contralateral nasal passage.
- closure of the velum will normally be maintained.
- the delivered gas flow enters one nasal cavity, passes beyond the posterior margin of the nasal septum, making a 180 degree turn behind the posterior margin of the nasal septum, and passes out the other nasal cavity.
- This re-direction of the gas flow results in a better deposition of substance, notably pharmaceuticals, to the posterior regions of the nasal turbinates and the nasal mucosa.
- the bi-directional deposition of substances, typically pharmaceuticals, and irrigation will also better reach all sinus ostia due to the anatomic locations and orientation of the sinus ostia, which can improve sinus ventilation and drainage which is essential to treat sinusitis and frequently accompanies inflammation of the nasal mucosa.
- the ostia and tubes to the ethmoidal and sphenoidal sinuses are located in the posterior region of the nasal airway and the uncinate projections covering the infundibulum, housing the maxillary, frontal and anterior ethmoid ostia, are tilted backwards.
- the driving positive pressure used will increase the deposition of pharmaceuticals at the sinus ostia, the sinus tubes leading into the sinuses and even in the sinuses themselves.
- the 180 degree re-direction of the flow behind the nasal septum particularly increases the deposition of substance on the roof of the nasopharynx where the adenoid is located and in proximity to the location of the tubal ostia to the auditory tubes connecting the nasopharynx and the middle ears.
- steroids have been shown to reduce the size of hypertrophic adenoids which are commonly found in paediatric subjects and can have a positive effect on secretory otitis media.
- Deposition of topical decongestants closer to the tubal ostia may also more efficiently decongest the auditory tubes and relieve the negative pressure in the middle ears which accompanies rhinitis and predisposes paediatric subjects to secretory otitis media and the consequential reduced hearing.
- Surgery for enlarged adenoids is frequently performed in children and the improved medical therapy of the present invention should reduce the necessity for surgery.
- a further advantage is that possible surplus substance, that is, substance which is not deposited, will be expelled out of the contralateral nostril, where it may be collected, if desired, and consequently not continue to the oral cavity and down into the gut as is the case with many other delivery techniques. In this way, the discomfort, and more importantly, the undesirable systemic exposure to the substance, where the substance is a medicament, will be reduced.
- irrigation by saline or other solutions can be performed more efficiently and with less spill and discomfort than the current techniques used for irrigation and flushing of the nasal airway.
- the present invention provides for simple and comfortable irrigation of the nasal mucosa with solutions, such as saline solutions, and other oils to remove secretions from the nasal mucosa and promote mucocilary function.
- the present invention provides a simple and effective means for the lavage of the nasal mucosa, such as to collect and diagnose mucosal entities, such as bacteria, viruses, cell components and inflammatory mediators.
- the exposure of the nasal mucosa to a positive pressure will open the narrow, and sometimes occluded, parts of the nasal passages, rather than cause a dynamic collapse which may happen during sniffing and inhalation.
- the dynamic positive pressure is at least 5 cm H O, preferably at least 50 cm H 2 O, more preferably at least 100 cm H 2 O, still more preferably at least 200 cm H O, yet more preferably 400 cm H 2 O and still yet more preferably 500 cm H 2 O.
- the dynamic positive pressure achieved by the present invention can be contrasted with the static pressure provided by the Valsalva procedure where there is no flow through the nasal airway.
- the use of warm and humid air as the gas flow is likely to be better tolerated and cause less irritation than room air or outdoor air, especially in cold climates.
- the humidity of the exhaled air may, in some instances, cause agglomeration of the powder.
- the surface properties of the powder could be modified, or the device could include a moisture-absorbing element, typically containing a desiccant such as silica, disposed upstream of the dispersion chamber.
- the moisture-absorbing element could be provided as a filter which acts as the flow resistor.
- the delivery device comprises transfer means which creates a gas flow of drier air, such as atmospheric air, as the delivery flow to the nasal airway.
- drier air such as atmospheric air
- transfer means which could be mechanical in nature, utilises the energy of the exhaled air to drive the atmospheric room air at the required flow rate, if necessary, to disperse the substance in the delivered air flow.
- agglomeration will be prevented or at least reduced to the same level as currently exhibited by dry powder inhalers.
- the distribution of the substance delivered to the nasal airway could be studied using standard techniques.
- use could be made of acoustic rhinometry or coloured fluids.
- the distribution of the delivered substance could even be determined by video endoscopy.
- distribution studies could also be performed by using appropriate radioactive materials and following the passage in the nasal cavities. The results of these studies could be used to optimise the flow rate, the shape or dimension of the device, in particular the nosepiece geometry, and the particle size distribution of the substance. The results of these studies could even be used to optimise subject acceptance.
- the delivery device may include a balloon or a similar pop-up device for indicating that the desired positive pressure has been attained, which balloon or pop-up device may improve the compliance in small children who are reluctant to use the device.
- the entraining gas flow can be provided by the exhalation air flow of another person, such as a parent, or even by the use of a pump or the like, while the child creates the required positive pressure in the oral cavity by inflating a balloon or pop-up device.
- Figure 1 schematically illustrates the anatomy of the upper respiratory tract of a human subject
- Figure 2 schematically illustrates a delivery device in accordance with a first embodiment of the present invention
- Figure 3 schematically illustrates a delivery device in accordance with a second embodiment of the present invention
- Figure 4 schematically illustrates a delivery device in accordance with a third embodiment of the present invention
- Figure 5 schematically illustrates a modified delivery unit for the above-described first to third embodiments of the present invention
- Figure 6 schematically illustrates a delivery device in accordance with a fourth embodiment of the present invention
- Figure 7 schematically illustrates a delivery device in accordance with a fifth embodiment of the present invention.
- Figure 8 schematically illustrates a delivery device in accordance with a sixth embodiment of the present invention.
- Figure 9 schematically illustrates a delivery device in accordance with a seventh embodiment of the present invention.
- Figure 2 illustrates a delivery device in accordance with a first embodiment of the present invention.
- the delivery device comprises an oral exhalation unit 20 and a substance delivery unit 22.
- the oral exhalation unit 20 and the delivery unit 22 are provided as separate components, but alternatively could be detachably coupled, for example by means of Velcro fasteners, connected, for example by means of screws and/or rivets, or even integrally formed.
- the oral exhalation unit 20 comprises a tubular section 24 and a mouthpiece 26 attached to one end of the tubular section 24.
- the mouthpiece 26 is a snap fit on the tubular section 24, but could equally be a screw fit.
- the tubular section 24 includes a flow resistor 28, in this embodiment a fixed baffle plate, configured to provide a sufficient resistance to exhalation therethrough by a subject as to cause the generation of a positive pressure in the oral cavity of the subject and the closure of the velum on exhalation by the subject.
- the flow resistor 28 could be a movable member, such as a biased flap, a resilient membrane or a damped wheel.
- the delivery unit 22 comprises a nosepiece 30, in this embodiment formed of a resilient material such as a polymeric material, for providing a tight sealing fit in one of the nostrils of the subject, a medicament supply unit 32 for supplying a gas flow entraining medicament at a predetermined pressure sufficient to open a flow path beyond the posterior margin of the nasal septum when delivered into one of the nasal cavities of the subject, and a tubular section 34 coupling the nosepiece 30 and the medicament supply unit 32.
- the nosepiece 30 can include an external olive or be shaped to cause the anterior region of the nasal cavity into which the nosepiece 30 is inserted to be enlarged.
- the nosepiece 30 can be shaped, for example by including swirl-inducing projections, to provide the exiting gas flow with an optimal flow pattern and particle size distribution.
- the nosepiece 30 is formed separately of the tubular section 34 to allow for replacement, but could alternatively be integrally formed.
- the nosepiece 30 is a snap fit on the tubular section 34, but could equally be a screw fit.
- the medicament supply unit 32 can comprise an aerosol spray generator for generating an aerosol spray of liquid droplets containing medicament, such as provided by a pressurised metered dose inhaler, or a pressurised gas source for entraining a metered dose of a dry powder containing medicament loaded thereinto, which powder could alternatively be loaded into a compartment in the tubular section 34.
- a subject grips the mouthpiece 26 in his or her lips and fits the nosepiece 30 into one of his or her nostrils.
- the subject then exhales through the mouthpiece 26, the flow of which exhaled air is resisted by the flow resistor 28 in the tubular section 24 such as to develop a positive pressure in the oral cavity of the subject, with the positive pressure being such as to develop a pressure differential across the velum sufficient to cause closure of the velum of the subject.
- the applicant has established that a positive pressure differential between the oral cavity and the nasal airway of about 5 cm H 2 0 is required to maintain the velum in the closed position.
- the medicament supply unit 32 is then actuated to deliver a gas flow entraining medicament through the nosepiece 30 and into the nasal airway of the subject.
- this gas flow is at such a pressure as to open a communication path beyond the posterior margin of the nasal septum such that the gas flow flows through the one nasal cavity, around the posterior margin of the nasal septum, in effect being re-directed through an angle of 180 degrees, and out of the other nasal cavity.
- this bi-directional flow provides for a much enhanced deposition of the medicament in the posterior region of the nasal airway.
- the medicament supply unit 32 can be omitted from the delivery unit 22, and instead a metered dose of dry powder loaded into a compartment in the tubular section 34, with the delivery air flow being provided by another person, such as the parent of a paediatric subject, blowing into the distal end of the tubular section 34.
- Figure 3 illustrates a delivery device in accordance with a second embodiment of the present invention.
- the delivery device comprises the oral exhalation unit 20 and the delivery unit 22 of the above-described first embodiment, and an outlet unit 36 for fitting to the other nostril of a subject to which the delivery unit 22 is fitted.
- the outlet unit 36 comprises a tubular section 38 and a nosepiece 40, in this embodiment formed of a resilient material such as a polymeric material, attached to one end of the tubular section 38 for providing a tight sealing fit in the other nostril of the subject.
- the nosepiece 40 is formed separately of the tubular section 38 to allow for replacement, but could alternatively be integrally formed.
- the nosepiece 40 is a snap fit on the tubular section 38, but could equally be a screw fit.
- the nosepiece 40 can include an external olive or be shaped to cause the anterior region of the other nasal cavity into which the nosepiece 40 is inserted to be enlarged.
- the tubular section 38 includes a flow resistor 41, in this embodiment a baffle plate, configured to provide a sufficient flow resistance to an exhalation flow therethrough as to cause the generation of a dynamic positive pressure in the nasal airway.
- a flow resistor 41 is adjustable to allow for adjustment of the level of the resistance and hence provide control of the dynamic pressure in the nasal airway.
- the flow resistor 41 could be a movable member, such as a biased flap, a resilient membrane or a damped wheel.
- the outlet unit 36 includes an indicator for providing at least one of a visual or audible signal on achieving a predetermined positive pressure upstream thereof, that is, in the nasal airway.
- the indicator comprises a whistle. In this way, the subject is provided with positive feedback of proper use of the device.
- a positive dynamic pressure is maintained in the nasal airway.
- This positive pressure advantageously acts to dilate the various ostia in the nasal airway, such as the sinus ostia and the tubal ostia, and the associated tubes, namely the sinus tubes and the auditory tubes, so as to promote the delivery of medicament thereto. Further, this positive pressure acts to improve deposition on the adenoid which can often obstruct the tubal ostia, the middle meatus which is a common location of nasal polyps, and the cleft to the olfactory cells.
- FIG. 4 illustrates a delivery device in accordance with a third embodiment of the present invention.
- the delivery device is very similar to that of the delivery device of the above-described second embodiment, and thus, in order to avoid unnecessary duplication of description, only the differences will be described in detail, with like parts being designated by like reference signs.
- This delivery device differs only in further comprising a pressure sensor 43, in this embodiment a pressure-sensitive spring or membrane, located in the tubular section 34 of the delivery unit 22 downstream of the medicament supply unit 32, and a control unit 44 coupled to the sensor 43 and the medicament supply unit 32.
- the control unit 44 is configured to control the flow rate of the delivery gas supplied by the medicament supply unit 32 in order to optimise the particle deposition efficiency in the nasal airway regardless of the degree of nasal congestion.
- the deposition efficiency of the medicament-containing particles is increased, referred to as the particle deposition efficiency. If, ordinarily, a flow rate of about 15 litres per minute is required to maximise the particle deposition efficiency, then in a congested nasal airway a lower flow rate, possibly 10 litres per minute, would be required and in an open nasal airway a higher flow rate, possibly 20 litres per minute, would be required.
- Figure 5 illustrates a modified oral exhalation unit 20 for the delivery devices of the above-described embodiments.
- This modified oral exhalation unit 20 differs in that the tubular section 24 includes a lateral opening 45 upstream of the flow resistor 28 and in further comprising, as an indicator, an inflatable figure 46 connected to the lateral opening 45, which figure 46 when inflated assumes a prominent position in the field of vision of the subject.
- the figure 46 is shown inflated.
- the oral exhalation unit 20 further comprises an inflation line 48 connected to the figure 46 which allows the figure 46 to be further inflated by another person, typically the parent of a paediatric subject, or a pump.
- the figure 46 could be of any kind which is brought into a prominent position on exhalation by the subject, typically a mechanically or electrically-operated figure.
- the figure 46 can be configured so as to be inflated on the subject achieving an optimum exhalation flow rate. In this way, the figure 46 acts as an indicator.
- the delivery device of this embodiment is the same as that of the above- described first embodiment.
- the developed pressure causes the figure 46 to be inflated and assume a prominent position in the field of vision of the subject.
- This appearance of the figure 46 is particularly appealing for paediatric subjects as the fun element of inflating the figure 46 can alleviate any unnecessary anxiety.
- Figure 6 illustrates a delivery device in accordance with a fourth embodiment of the present invention.
- the delivery device comprises a chamber 50 which includes an inlet 52 and an outlet 54, a mouthpiece 56 connected to the inlet 52 and a nosepiece 58 connected to the outlet 54.
- the nosepiece 58 is configured to provide a tight sealing fit in one of the nostrils of a subject.
- the chamber 50 includes a flow resistor 60, in this embodiment a plurality of baffle plates, and a medicament-receiving compartment 62 downstream of the flow resistor 60 for containing a metered dose of a dry powder containing medicament to be delivered to the nasal airway of a subject.
- the nosepiece 58 is formed of a resilient material such as a polymeric material.
- the chamber 50 may include a desiccant.
- the flow resistor 60 can be provided by a moisture-absorbing filter.
- a subject grips the mouthpiece 56 in his or her lips and fits the nosepiece 58 into one of his or her nostrils. The subject then exhales through the mouthpiece 56, the flow of which exhaled air is resisted by the flow resistor 60 in the chamber 50 and the resistance of the nasal airway such as to develop a positive pressure in the oral cavity of the subject sufficient to cause closure of the velum.
- the exhaled air after passing the flow resistor 60, then entrains the powdered medicament in the medicament- receiving compartment 62, and this air flow entraining medicament then passes through the nosepiece 58 into the nasal airway of the subject.
- the exhaled air entering the nasal airway is at a pressure sufficient to open a communication path beyond the posterior margin of the nasal septum such that the air flow flows through the one nasal cavity, around the posterior margin of the nasal septum, in effect being re-directed through an angle of 180 degrees, and out of the other nasal cavity.
- this bi-directional flow provides for a much enhanced deposition of the medicament in the posterior margin of the nasal airway.
- the delivery device includes a pressure-triggered valve, preferably located in the mouthpiece 56, which is configured to open only when a predetermined positive pressure has been developed by the exhalation of the subject, typically at a positive pressure of about 10 cm H 2 O.
- a pressure-triggered valve preferably located in the mouthpiece 56, which is configured to open only when a predetermined positive pressure has been developed by the exhalation of the subject, typically at a positive pressure of about 10 cm H 2 O.
- the delivery device can include an outlet unit for providing a flow resistor downstream of the other nostril of the subject such as to maintain a positive dynamic pressure in the nasal airway.
- FIG. 7 illustrates a delivery device in accordance with a fifth embodiment of the present invention.
- the delivery device comprises an oral exhalation unit 70 through which a subject exhales to close his or her velum and a medicament delivery unit 72 for supplying an air flow entraining medicament to the nasal airway of the subject.
- the oral exhalation unit 70 comprises a tubular section 74 and a mouthpiece 76 attached to one end of the tubular section 74.
- the mouthpiece 76 which is gripped in the lips of the subject, is formed separately of the tubular section 74 to allow for replacement, but could alternatively be integrally formed therewith.
- the mouthpiece 76 is a snap fit on the tubular section 74, but could equally be a screw fit.
- the tubular section 74 includes a flow resistor 78, in this embodiment a gearwheel, configured to rotate on exhalation by the subject and yet provide sufficient resistance to the exhalation flow as to cause the generation of a positive pressure in the oral cavity of the subject sufficient to maintain the required positive pressure differential between the oral cavity and the nasal airway and thereby maintain the velum in the closed position.
- a flow resistor 78 in this embodiment a gearwheel, configured to rotate on exhalation by the subject and yet provide sufficient resistance to the exhalation flow as to cause the generation of a positive pressure in the oral cavity of the subject sufficient to maintain the required positive pressure differential between the oral cavity and the nasal airway and thereby maintain the velum in the closed position.
- the delivery unit 72 comprises a tubular section 80 and a nosepiece 82, in this embodiment formed of a resilient material such as a polymeric material, for providing a tight sealing fit in one of the nostrils of the subject, attached to one end of the tubular section 80.
- the nosepiece 82 is formed separately of the tubular section 80 to allow for replacement, but could alternatively be integrally formed therewith.
- the nosepiece 82 is a snap fit on the tubular section 80, but could equally be a screw fit.
- the nosepiece 82 can include an external olive or be shaped to cause the anterior region of the nasal cavity, into which the nosepiece 82 is inserted, to be enlarged.
- the nosepiece 82 can be shaped, for example by including swirl-inducing projections, to provide the exiting air flow with an optimal flow pattern and particle size distribution.
- the tubular section 80 includes an impeller 84 coupled to the gearwheel 78 in the tubular section 74 of the oral exhalation unit 70, such as to be rotated on rotation of the gearwheel 78 to draw air into the tubular section 80 and provide an air flow therethrough at a pressure sufficient to open the flow path beyond the posterior margin of the nasal septum when delivered into one of the nasal cavities of the subject.
- the delivery unit 72 further comprises a dispensing unit 86 for dispensing a metered dose of a dry powder containing medicament to the tubular section 80 upstream of the impeller 84.
- the dispensing unit 86 is manually actuated to supply a metered dose of dry powder containing medicament into the tubular section 80, but could alternatively be configured to the driven by the gearwheel 78 so as to avoid the need for any manual intervention on the part of the subject.
- a subject grips the mouthpiece 76 in his or her lips and fits the nosepiece 82 into one of his or her nostrils.
- the subject then exhales through the mouthpiece 76, the flow of which exhaled air is resisted by the gearwheel 78 such as to develop a positive pressure in the oral cavity of the subject sufficient to cause the velum of the subject to close.
- the exhaled air causes rotation of the gearwheel 78 which in turn causes rotation of the impeller 84, and the rotation of the impeller 84 develops an air flow through the tubular section 80 which entrains the metered dose of dry powder containing medicament and delivers the same through the nosepiece 82 to the nasal airway of the subject.
- this air flow is at a pressure sufficient to open a communication path beyond the posterior margin of the nasal septum such that the air flow flows through the one nasal cavity, around the posterior margin of the nasal septum, in effect being re-directed through an angle of 180 degrees, and out of the other nasal cavity.
- this bi-directional flow provides for a much enhanced deposition of the medicament in the posterior region of the nasal cavity.
- the gearwheel 78 is configured such that rotation thereof is prevented until a predetermined flow rate has been developed which is sufficient to ensure that the entraining gas flow developed by the impeller 84 is optimal.
- This configuration advantageously ensures an optimal particle deposition efficiency and avoids the possibility of medicament being delivered to the nasal airway with the velum in the open position so as to reduce the risk of undesirably depositing medicament outside the nasal airway.
- Figure 8 illustrates a delivery device in accordance with a sixth embodiment of the present invention.
- the delivery device comprises a housing 90 for housing a blister pack element 92 which includes a plurality of blisters 94 therein, each containing powder containing medicament, and a tubular section 96 in communication with one of the blisters 94 when open, one end of which tubular section 96 provides a mouthpiece 98 which in use is gripped in the lips of a subject.
- the tubular section 96 includes an element 100 movably disposed therein between a first, normally closed position and a second, open position.
- the element 100 comprises a propeller or the like rotatably mounted on a threaded shaft and normally biased to the closed position by a compression spring.
- the element 100 is configured both to function as a flow resistor and a valve.
- the element 100 is configured to move to the medicament-releasing open position by rotation along the threaded shaft against the bias of the compression spring, with the powder being entrainable by an air flow only when the exhalation flow exceeds a predetermined flow rate.
- the flow rate preferably in the range of about 5 to 20 litres per minute, at which the powder containing medicament is entrained by the air flow is a function, in inverse relation, to the driving pressure which is itself a function of the nasal resistance as described hereinabove.
- this configuration advantageously provides for an optimal particle deposition efficiency in releasing the powder containing medicament at the optimal flow rate, and avoids the possibility of medicament being delivered to the nasal airway with the velum in the open position.
- the delivery device further comprises a nosepiece 102, in this embodiment formed of a resilient material such as a polymeric material, for providing a tight sealing fit in one of the nostrils of the subject attached to the other end of the tubular section 96 downstream of the element 100.
- the nosepiece 102 is formed separately of the tubular section 96 to allow for replacement, but could alternatively be integrally formed therewith.
- the nosepiece 102 is a snap fit on the tubular section 96, but could equally be a screw fit.
- the nosepiece 102 can include an external olive or be shaped to cause the anterior region of the nasal cavity into which the nosepiece 102 is inserted to be enlarged.
- the nosepiece 102 can be shaped, for example by including swirl-inducing projections, to provide the exiting air flow with an optimal flow pattern and particle size distribution.
- the delivery device further comprises a blister opening mechanism 104 for opening the blister 94 in communication with the tubular section 96.
- the blister opening mechanism 104 is manually operated by the subject prior to delivery.
- a subject grips the mouthpiece 98 in his or her lips and fits the nosepiece 102 into one of his or her nostrils.
- the subject then exhales through the mouthpiece 98, the flow of which exhaled air is resisted by the element 100 until a predetermined flow rate has been achieved.
- a predetermined flow rate has been achieved, at which flow rate the velum is in the closed position, the element 100 is in the open position and the exhaled air flow entrains the powdered medicament in the blister 94 and delivers the same through the nosepiece 102 to the nasal airway.
- the driving pressure of this air flow is at a level sufficient to maintain a communication path beyond the posterior margin of the nasal septum such that the air flow flows through the one nasal cavity, around the posterior margin of the nasal septum, in effect being re-directed through an angle of 180 degrees, and out of the other nasal cavity.
- this bi-directional flow provides for a much enhanced deposition of the medicament in the posterior margin of the nasal cavity.
- the delivery device includes a blister pack advancement mechanism, operated by movement of the mouthpiece 98, for rotating the blister pack element 92 such that another unused blister 94 is located at the delivery position.
- the blister pack advancement mechanism can be coupled to the blister opening mechanism 104 such as automatically to open the blister 94, and thereby avoid the need for any further intervention by the subject.
- the delivery device can include an outlet unit for providing a flow resistor downstream of the other nostril of the subject such as to maintain a positive dynamic pressure in the nasal airway.
- the blister pack element 92 can be omitted and the housing 90 instead provided with a chamber which is in communication with the tubular section 96 and into which a metered dose of dry powder containing medicament can be loaded.
- the powder in the chamber is entrained on the element 100 being driven to the second position and the blister pack advancement mechanism is configured to meter a dose of powder containing medicament into the chamber on operation thereof.
- the present invention can be broadly based on any dry powder inhaler, such as the TurbuhalerTM as manufactured by AstraZeneca PLC, the AccuhalerTM as manufactured by Glaxo PLC or the TwisthalerTM as manufactured by Schering AG, where the usual mouthpiece is replaced by a nosepiece and a mouthpiece is provided in communication with the air inlet of the inhaler such as to utilise the air exhaled by a subject as the entraining delivery air.
- any dry powder inhaler such as the TurbuhalerTM as manufactured by AstraZeneca PLC, the AccuhalerTM as manufactured by Glaxo PLC or the TwisthalerTM as manufactured by Schering AG, where the usual mouthpiece is replaced by a nosepiece and a mouthpiece is provided in communication with the air inlet of the inhaler such as to utilise the air exhaled by a subject as the entraining delivery air.
- Figure 9 illustrates a delivery device in accordance with a seventh embodiment of the present invention.
- the delivery device comprises a housing 110 and a tubular section 112 extending through the housing 110, one end of which provides a mouthpiece 114 which in use is gripped in the lips of a subject.
- the tubular section 112 includes an element 116 movably disposed therein between a first, normally closed position and a second, trigger position.
- the element 116 comprises a propeller or the like rotatably mounted on a threaded shaft and normally biased to the closed position by a compression spring.
- the element 116 is configured to function as a flow resistor, a valve and a trigger for the delivery of an aerosol spray into the tubular section 112 as will be described in detail hereinbelow.
- the element 116 is configured to move to the medicament-releasing open position, by rotation along the threaded shaft against the bias of the compression spring, only when the exhalation flow exceeds a predetermined flow rate.
- the flow rate at which the medicament is released preferably in the range of about 5 to 20 litres per minute, is a function, in inverse relation, to the driving pressure which is itself a function of the nasal resistance as described hereinabove.
- this configuration advantageously provides for an optimal particle deposition efficiency in releasing the medicament at the optimal flow rate, and avoids the possibility of medicament being delivered to the nasal airway with the velum in the open position.
- the tubular section 112 further includes a nozzle block 117 for providing an aerosol spray through the tubular section 112 along the longitudinal axis thereof.
- the nozzle block 117 receives the valve stem 122 of an aerosol canister 120.
- the delivery device further comprises a known aerosol canister 120 used to deliver metered volumes of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing medicament, either as a suspension or as a solution.
- the aerosol canister 120 comprises a main body 121 which contains a volume of propellant under pressure containing medicament, a valve stem 122 through which the propellant containing medicament is in use delivered on relative movement of the main body 121 and the valve stem 122, and a metering valve 124 for metering a predetermined volume of propellant containing medicament to the valve stem 122 on movement thereof.
- a propellant preferably a hydrofluoroalkane (HFA) propellant or the like
- the aerosol canister 120 comprises a main body 121 which contains a volume of propellant under pressure containing medicament, a valve stem 122 through which the propellant containing medicament is in use delivered on relative movement of the main body 121 and the valve stem 122, and a metering valve
- the delivery device further comprises a trigger mechanism 126 for relatively moving the main body 121 and the valve stem 122 of the aerosol canister 120 to effect the delivery of a metered volume of propellant containing medicament through the nozzle block 117.
- the trigger mechanism 126 comprises a resilient element 128 for loading the main body 121 with an actuation force, and a lever assembly 130 coupled to the movable element 116 to cause the release of the actuation force provided by the resilient element 128 on movement of the movable element 116 from the closed position to the trigger position.
- the delivery device further comprises a nosepiece 132, in this embodiment formed of a resilient material such as a polymeric material, for providing a tight sealing fit in one of the nostrils of the subject, attached to the other end of the tubular section 112 downstream of the movable element 116.
- the nosepiece 132 is formed separately of the tubular section 112 to allow for replacement, but could alternatively be integrally formed therewith.
- the nosepiece 132 is a snap fit on the tubular section 112, but could equally be a screw fit.
- the nosepiece 132 can include an external olive or be shaped to cause the anterior region of the nasal cavity into which the nosepiece 132 is inserted to be enlarged.
- the nosepiece 132 can be shaped, for example by including swirl-inducing projections, to provide the exiting air flow with an optimal flow pattern and particle size distribution.
- a subject primes the trigger mechanism 126, grips the mouthpiece 114 in his or her lips and fits the nosepiece 132 into one of his or her nostrils. The subject then exhales through the mouthpiece 114, the flow of which exhaled air is resisted by the movable element 116 until a predetermined flow rate has been achieved.
- the movable element 116 is in the open position, triggering the movement of the lever assembly 130 and hence the relative movement of the main body 121 and the valve stem 122 of the canister 120 to deliver a metered volume of propellant containing medicament to the nozzle block 117 to generate an aerosol spray of liquid droplets containing medicament through the nosepiece 132 to the nasal airway.
- This aerosol flow is at a pressure sufficient to maintain a communication path beyond the posterior margin of the nasal septum such that the flow flows through the one nasal cavity, around the posterior margin of the nasal septum, in effect being re- directed through an angle of 180 degrees, and out of the other nasal cavity.
- this bi-directional flow provides for a much enhanced deposition of the medicament in the posterior margin of the nasal cavity.
- the present invention can be broadly based on any breath-actuated pressurised metered dose inhaler, where the usual mouthpiece is replaced by a nosepiece and a mouthpiece is provided in communication with the air inlet of the inhaler such as both to trigger the triggering mechanism and utilise the air exhaled by a subject as the entraining delivery air.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
- Massaging Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Eye Examination Apparatus (AREA)
- External Artificial Organs (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Window Of Vehicle (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Seal Device For Vehicle (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200030636T SI1161274T1 (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
JP2000602333A JP4543553B2 (en) | 1999-03-03 | 2000-03-03 | Nasal infeed device |
DE60017099T DE60017099T2 (en) | 1999-03-03 | 2000-03-03 | NASAL ADMINISTRATOR |
AU28227/00A AU766410B2 (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
AT00906570T ATE285810T1 (en) | 1999-03-03 | 2000-03-03 | NASAL ADMINISTRATION DEVICE |
CA002364009A CA2364009C (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
IL14498800A IL144988A0 (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
MXPA01008849A MXPA01008849A (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device. |
BRPI0008650-9A BR0008650B1 (en) | 1999-03-03 | 2000-03-03 | nasal transmission device. |
US09/700,532 US6715485B1 (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
DK00906570T DK1161274T3 (en) | 1999-03-03 | 2000-03-03 | Nasal administration device |
EP00906570A EP1161274B1 (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
NZ514442A NZ514442A (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
IL144988A IL144988A (en) | 1999-03-03 | 2001-08-20 | Nasal delivery device |
NO20014182A NO20014182L (en) | 1999-03-03 | 2001-08-28 | Nasal administration device |
HK02100833.9A HK1039459B (en) | 1999-03-03 | 2002-02-04 | Nasal delivery device |
US10/813,326 US8327844B2 (en) | 1999-03-03 | 2004-03-30 | Nasal delivery method |
US11/445,994 US8555878B2 (en) | 1999-03-03 | 2006-06-02 | Nasal delivery device |
US11/445,812 US8555877B2 (en) | 1999-03-03 | 2006-06-02 | Nasal delivery device |
US11/445,993 US9119932B2 (en) | 1999-03-03 | 2006-06-02 | Nasal delivery device |
US11/446,424 US9072857B2 (en) | 1999-03-03 | 2006-06-02 | Nasal delivery device |
US12/955,546 US20120073571A1 (en) | 1999-03-03 | 2010-11-29 | Nasal delivery device |
US14/725,602 US20160095993A1 (en) | 1999-03-03 | 2015-05-29 | Nasal delivery device |
US14/978,230 US20160250408A1 (en) | 1999-03-03 | 2015-12-22 | Nasal delivery method |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9904906.6 | 1999-03-03 | ||
GBGB9904906.6A GB9904906D0 (en) | 1999-03-03 | 1999-03-03 | Device |
GBGB9911686.5A GB9911686D0 (en) | 1999-05-19 | 1999-05-19 | Device |
GB9911686.5 | 1999-05-19 |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/700,532 A-371-Of-International US6715485B1 (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
US10469114 Continuation-In-Part | 2002-02-26 | ||
PCT/IB2002/001612 Continuation-In-Part WO2002068031A2 (en) | 1999-03-03 | 2002-02-26 | Nasal delivery devices |
PCT/IB2002/003849 Continuation-In-Part WO2003020350A1 (en) | 1999-03-03 | 2002-09-06 | Nasal delivery device |
US10/489,187 Continuation-In-Part US7841337B2 (en) | 1999-03-03 | 2002-09-06 | Breath-actuated nasal delivery device |
US10/813,326 Continuation US8327844B2 (en) | 1999-03-03 | 2004-03-30 | Nasal delivery method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000051672A1 true WO2000051672A1 (en) | 2000-09-08 |
Family
ID=26315212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2000/000273 WO2000051672A1 (en) | 1999-03-03 | 2000-03-03 | Nasal delivery device |
Country Status (25)
Country | Link |
---|---|
US (8) | US6715485B1 (en) |
EP (6) | EP1180378B8 (en) |
JP (2) | JP4543553B2 (en) |
KR (1) | KR100692422B1 (en) |
CN (2) | CN1217712C (en) |
AT (3) | ATE514445T1 (en) |
AU (1) | AU766410B2 (en) |
BR (1) | BR0008650B1 (en) |
CA (1) | CA2364009C (en) |
CY (1) | CY1111201T1 (en) |
DE (2) | DE60045216D1 (en) |
DK (3) | DK1180378T3 (en) |
ES (3) | ES2600357T3 (en) |
GB (1) | GB2349092B (en) |
HK (2) | HK1039459B (en) |
ID (1) | ID30286A (en) |
IL (2) | IL144988A0 (en) |
MX (1) | MXPA01008849A (en) |
NO (1) | NO20014182L (en) |
NZ (1) | NZ514442A (en) |
PL (2) | PL203959B1 (en) |
PT (2) | PT1161274E (en) |
SI (2) | SI1180378T1 (en) |
TR (1) | TR200102563T2 (en) |
WO (1) | WO2000051672A1 (en) |
Cited By (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002068029A2 (en) * | 2001-02-26 | 2002-09-06 | Optinose As | Nasal delivery devices |
WO2003000310A2 (en) | 2001-06-12 | 2003-01-03 | Optinose As | Nasal devices |
WO2003020350A1 (en) | 2001-09-06 | 2003-03-13 | Optinose As | Nasal delivery device |
WO2003082393A1 (en) * | 2002-03-28 | 2003-10-09 | Optinose As | Nasal devices |
WO2003084591A1 (en) | 2002-04-04 | 2003-10-16 | Optinose As | Nasal devices |
WO2003090812A2 (en) * | 2002-04-25 | 2003-11-06 | Optinose As | Nasal devices |
WO2004020029A1 (en) * | 2002-08-27 | 2004-03-11 | Pari GmbH Spezialisten für effektive Inhalation | Therapeutic aerosol device |
WO2004060433A2 (en) | 2003-01-02 | 2004-07-22 | Optinose As | Delivery devices |
WO2004103447A2 (en) * | 2003-05-20 | 2004-12-02 | Optinose As | Delivery device and method |
WO2005016423A2 (en) * | 2003-08-14 | 2005-02-24 | Optinose As | Delivery devices |
WO2005021059A2 (en) | 2003-08-28 | 2005-03-10 | Optinose As | Delivery devices |
US6959708B1 (en) | 1999-11-08 | 2005-11-01 | Capnia, Incorporated | Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments |
GB2418147A (en) * | 2004-09-15 | 2006-03-22 | Optinose As | Nasal delivery device with mouthpiece |
US7017573B1 (en) | 1999-07-12 | 2006-03-28 | Capnia, Incorporated | Methods and apparatus for relieving headaches, rhinitis and other common ailments |
WO2006090149A2 (en) * | 2005-02-23 | 2006-08-31 | Optinose As | Nasal delivery device |
WO2007001585A1 (en) * | 2005-06-27 | 2007-01-04 | Kos Life Sciences, Inc. | Breath actuated nasal drug delivery system |
WO2007093791A2 (en) * | 2006-02-14 | 2007-08-23 | Optinose As | Delivery device and method |
GB2435835A (en) * | 2006-03-06 | 2007-09-12 | Optinose As | Nosepiece for nasal delivery device |
WO2007116002A1 (en) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Inhaler |
WO2007118801A1 (en) | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim International Gmbh | Inhaler |
WO2007141541A1 (en) * | 2006-06-08 | 2007-12-13 | Optinose As | Intranasal administration |
GB2440316A (en) * | 2006-07-25 | 2008-01-30 | Optinose As | Nasal inhaler with scrubber |
WO2008030837A1 (en) * | 2006-09-06 | 2008-03-13 | Abbott Respiratory Llc | Variable dose aerosol drug canister |
WO2008091588A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
GB2448183A (en) * | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
WO2008122791A2 (en) * | 2007-04-05 | 2008-10-16 | Optinose As | Nasal delivery |
DE102007033860A1 (en) | 2007-07-20 | 2009-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Test arrangement for testing sealing between mouthpiece of inhaler and user's lips has channel for secondary air around user's lips with second flow measurement device |
US7481218B2 (en) | 2002-07-02 | 2009-01-27 | Optinose As | Nasal devices |
DE202008015493U1 (en) | 2008-11-21 | 2009-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | folding |
GB2453389A (en) * | 2006-11-28 | 2009-04-08 | Optinose As | Nasal delivery system with a replaceable nosepiece unit |
WO2009044172A1 (en) | 2007-10-03 | 2009-04-09 | Optinose As | Nasal delivery devices |
DE102007052871A1 (en) | 2007-11-02 | 2009-05-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Capsule for receiving pharmaceutical drug formulations |
GB2470486A (en) * | 2006-11-28 | 2010-11-24 | Optinose As | Nasal delivery system with replaceable nosepiece unit |
FR2952042A1 (en) * | 2009-11-03 | 2011-05-06 | Valois Sas | DEVICE FOR DISPENSING FLUID PRODUCT. |
US8006698B2 (en) | 2006-01-09 | 2011-08-30 | Pari Gmbh Spezialisten Fuer Effektive Inhalation | Aerosol therapy device |
FR2960423A1 (en) * | 2010-05-27 | 2011-12-02 | Laurent Michel Marie Charroin | Device for administrating liquid charged or not charged with paranasal sinus substances, has mechanical unit generating movement of fluid directed toward otorhinolaryngology sphere in fluid supply circuit |
US8096968B2 (en) | 1999-11-08 | 2012-01-17 | Capnia, Inc. | Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces |
WO2012035427A1 (en) | 2010-09-14 | 2012-03-22 | Optinose As | Nasal delivery |
WO2012123819A1 (en) | 2011-03-15 | 2012-09-20 | Optinose As Et Al | Nasal delivery |
US8347878B2 (en) | 2007-04-11 | 2013-01-08 | Pari GmbH Spezialisten für effektive Inhalation | Aerosol therapy device |
US8397717B2 (en) | 2005-10-28 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Inhaler with mouthpiece having a microbiological protective function |
US8398580B2 (en) | 1999-11-08 | 2013-03-19 | Capnia, Inc. | Methods and apparatus for treating rhinitis |
WO2013124491A1 (en) | 2012-02-24 | 2013-08-29 | Optinose As | Nasal delivery devices |
WO2013124492A1 (en) | 2012-02-24 | 2013-08-29 | Optinose As | Nasal delivery devices |
WO2013124493A1 (en) | 2012-02-24 | 2013-08-29 | Optinose As | Nasal delivery devices |
EP2656867A2 (en) | 2006-04-11 | 2013-10-30 | Boehringer Ingelheim Pharma GmbH & Co. KG | Mouthpiece for an inhalator |
WO2014155192A2 (en) | 2013-03-26 | 2014-10-02 | Optinose As | Nasal administration |
US8852143B2 (en) | 2004-04-21 | 2014-10-07 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US8858586B2 (en) | 2004-04-21 | 2014-10-14 | Acclarent, Inc. | Methods for enlarging ostia of paranasal sinuses |
US8864787B2 (en) | 2004-04-21 | 2014-10-21 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
US8870893B2 (en) | 2004-04-21 | 2014-10-28 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat |
US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
US8945088B2 (en) | 2004-04-21 | 2015-02-03 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
US8961398B2 (en) | 2004-04-21 | 2015-02-24 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US8968269B2 (en) | 2005-09-23 | 2015-03-03 | Acclarent, Inc. | Multi-conduit balloon catheter |
US8979888B2 (en) | 2008-07-30 | 2015-03-17 | Acclarent, Inc. | Paranasal ostium finder devices and methods |
US9038630B2 (en) | 2006-11-28 | 2015-05-26 | Optinose As | Delivery devices |
US9039657B2 (en) | 2004-08-04 | 2015-05-26 | Acclarent, Inc. | Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US9072626B2 (en) | 2009-03-31 | 2015-07-07 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US9107574B2 (en) | 2004-04-21 | 2015-08-18 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
US9265407B2 (en) | 2004-04-21 | 2016-02-23 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9272104B2 (en) | 2006-03-23 | 2016-03-01 | Optinose As | Nasal delivery |
US9308361B2 (en) | 2005-01-18 | 2016-04-12 | Acclarent, Inc. | Implantable devices and methods for treating sinusitis and other disorders |
US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
USD759805S1 (en) | 2013-05-23 | 2016-06-21 | Optinose As | Nosepiece unit |
US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US9433437B2 (en) | 2013-03-15 | 2016-09-06 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US9463068B2 (en) | 2007-05-08 | 2016-10-11 | Acclarent, Inc. | Methods and devices for protecting nasal turbinates |
US9468362B2 (en) | 2004-04-21 | 2016-10-18 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9604017B2 (en) | 2005-11-15 | 2017-03-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Needle for piercing a powder capsule for inhalation |
US9615775B2 (en) | 2007-04-30 | 2017-04-11 | Acclarent, Inc. | Methods and devices for ostium measurements |
US9629684B2 (en) | 2013-03-15 | 2017-04-25 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US9636258B2 (en) | 2009-03-31 | 2017-05-02 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
US9649477B2 (en) | 2004-04-21 | 2017-05-16 | Acclarent, Inc. | Frontal sinus spacer |
EP1988953B1 (en) * | 2006-02-14 | 2017-07-19 | Optinose AS | Delivery device |
US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
US9826999B2 (en) | 2004-04-21 | 2017-11-28 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
US9861793B2 (en) | 2008-03-10 | 2018-01-09 | Acclarent, Inc. | Corewire design and construction for medical devices |
US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
US10206821B2 (en) | 2007-12-20 | 2019-02-19 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
AU2017200564B2 (en) * | 2004-09-15 | 2019-03-28 | Optinose As | Nasal delivery devices |
EP3546000A1 (en) | 2006-01-19 | 2019-10-02 | Optinose AS | Nasal administration |
US10524814B2 (en) | 2009-03-20 | 2020-01-07 | Acclarent, Inc. | Guide system with suction |
US10631756B2 (en) | 2004-04-21 | 2020-04-28 | Acclarent, Inc. | Guidewires for performing image guided procedures |
US10639438B2 (en) | 2006-11-28 | 2020-05-05 | Optinose As | Delivery devices |
US10874838B2 (en) | 2004-04-21 | 2020-12-29 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US10940277B2 (en) | 2014-11-19 | 2021-03-09 | Optinose As | Intranasal administration |
US11065061B2 (en) | 2004-04-21 | 2021-07-20 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
US11529502B2 (en) | 2004-04-21 | 2022-12-20 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
WO2023135237A1 (en) | 2022-01-14 | 2023-07-20 | Cybin Irl Limited | Tryptamine compositions and methods |
WO2023156453A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
WO2023156450A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
EP4233950A1 (en) | 2014-06-25 | 2023-08-30 | Optinose, Inc. | Nasal administration |
WO2023186963A1 (en) | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
KR100692422B1 (en) | 1999-03-03 | 2007-03-09 | 옵티노즈 에이에스 | Nasal delivery device |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US7335181B2 (en) | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US20110301569A1 (en) * | 2001-01-20 | 2011-12-08 | Gordon Wayne Dyer | Methods and apparatus for the CVCS |
SE0101825D0 (en) * | 2001-05-22 | 2001-05-22 | Astrazeneca Ab | An inhalation device |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
GB2395909B (en) * | 2001-09-06 | 2005-02-16 | Optinose As | Nasal delivery device |
US7231919B2 (en) * | 2001-09-28 | 2007-06-19 | Kurve Technology, Inc. | Particle dispersion device for nasal delivery |
KR100956002B1 (en) * | 2001-12-31 | 2010-05-04 | 씨엔에스, 인코포레이티드 | Nasal devices including dilation and user communication and methods of using same |
US6760556B2 (en) | 2002-07-16 | 2004-07-06 | Cf Technologies | Sealing member and toner container provided with such a sealing member |
AU2003249623A1 (en) | 2002-05-09 | 2003-12-12 | Kurve Technology, Inc. | Particle dispersion chamber for nasal nebulizer |
GB0215904D0 (en) * | 2002-07-09 | 2002-08-21 | Team Holdings Uk Ltd | Drug delivery system and method |
US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
US8317816B2 (en) | 2002-09-30 | 2012-11-27 | Acclarent, Inc. | Balloon catheters and methods for treating paranasal sinuses |
AU2004222340B2 (en) | 2003-03-14 | 2009-11-12 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
GB2400565B (en) * | 2003-04-17 | 2005-03-02 | Bespak Plc | Nasal drug delivery |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7353826B2 (en) * | 2003-08-08 | 2008-04-08 | Cardinal Health 205, Inc. | Sealing nasal cannula |
NZ549588A (en) | 2004-02-24 | 2009-03-31 | Microdose Technologies Inc | Directional flow sensor inhaler |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
CA2563493A1 (en) * | 2004-05-11 | 2005-11-24 | Sensormedics Corporation | Intermittent dosing of nitric oxide gas |
US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
WO2006058059A2 (en) | 2004-11-23 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
GB0427856D0 (en) * | 2004-12-20 | 2005-01-19 | Glaxo Group Ltd | Maniflod for use in medicament dispenser |
GB0427853D0 (en) * | 2004-12-20 | 2005-01-19 | Glaxo Group Ltd | Manifold for use in medicament dispenser |
GB0427858D0 (en) * | 2004-12-20 | 2005-01-19 | Glaxo Group Ltd | Manifold for use in medicament dispenser |
KR100675379B1 (en) * | 2005-01-25 | 2007-01-29 | 삼성전자주식회사 | Printing system and printing method |
CA2598666A1 (en) * | 2005-02-23 | 2006-08-31 | Alza Corporation | Intranasal administration of active agents to the central nervous system |
US20090136505A1 (en) * | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
CN101189016B (en) | 2005-04-04 | 2013-03-27 | 因特尔赛克特耳鼻喉公司 | Device and methods for treating paranasal sinus conditions |
BRPI0607017B8 (en) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | pharmaceutical composition comprising memantine and donezepil, and their use for the treatment of snc-related conditions |
US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
JP2009509535A (en) * | 2005-09-27 | 2009-03-12 | アムニクス, インコーポレイテッド | Proteinaceous drugs and their use |
US20070068524A1 (en) * | 2005-09-28 | 2007-03-29 | Microdrug Ag | Inhaler for moisture sensitive drugs |
CA2623658A1 (en) * | 2005-09-28 | 2007-04-05 | Mederio Ag | Inhaler device for moisture sensitive drugs and method of operating an inhaler device |
WO2007057763A2 (en) * | 2005-11-18 | 2007-05-24 | Pulmonox Technologies Corporation | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
US7640934B2 (en) * | 2005-12-02 | 2010-01-05 | Carefusion 2200, Inc. | Infant nasal interface prong device |
AR058289A1 (en) * | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | COLLECTOR TO BE USED IN MEDICINAL DISPENSER |
AR058290A1 (en) * | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | MEDICINAL DISPENSER |
GB0604319D0 (en) * | 2006-03-03 | 2006-04-12 | Optinose As | Nasal delivery |
US8486050B2 (en) * | 2006-03-17 | 2013-07-16 | Jackey Chiou | Bubble-type nose cleaner |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
US8535707B2 (en) * | 2006-07-10 | 2013-09-17 | Intersect Ent, Inc. | Devices and methods for delivering active agents to the osteomeatal complex |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
GB2476731B (en) * | 2006-11-28 | 2011-08-24 | Optinose As | Delivery devices |
WO2008070516A2 (en) * | 2006-12-01 | 2008-06-12 | Abbott Laboratories | Dose selective breath actuated inhaler |
US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
US8048023B2 (en) * | 2007-03-06 | 2011-11-01 | Rhinosystems Inc. | Systems and methods for nasal irrigation |
US8714153B2 (en) * | 2007-04-16 | 2014-05-06 | Ric Investments, Llc | Method for selecting a device adapted to treat disordered breathing |
WO2008144106A1 (en) * | 2007-05-16 | 2008-11-27 | Aradigm Corporation | Burst valve for aerosol device |
US10293123B2 (en) | 2007-05-23 | 2019-05-21 | Shin Nippon Biomedical Laboratories, Ltd. | Test substance administration system for animal experiment |
EP2185701A4 (en) * | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | Compositions and methods for modifying properties of biologically active polypeptides |
US8585730B2 (en) | 2007-12-18 | 2013-11-19 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US8757146B2 (en) * | 2008-02-07 | 2014-06-24 | University Of Washington Through Its Center For Commercialization | Circumferential aerosol device |
CA2732355A1 (en) | 2008-08-01 | 2010-02-04 | Intersect Ent, Inc. | Methods and devices for crimping self-expanding devices |
FR2938770B1 (en) * | 2008-11-27 | 2011-08-26 | Diffusion Tech Francaise Sarl | NASAL OR NASOSINUSIAN GAS AND AEROSOL DELIVERY DEVICE |
US20100234829A1 (en) * | 2008-12-09 | 2010-09-16 | Wayne Jeffery Perry | Dispenser head for nasal cleansing |
LT2393828T (en) | 2009-02-03 | 2017-01-25 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US8957021B2 (en) | 2009-02-03 | 2015-02-17 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
WO2010126586A1 (en) * | 2009-04-27 | 2010-11-04 | Aardvark Medical, Llc | Irrigation and aspiration devices and methods |
CN102639168A (en) * | 2009-04-27 | 2012-08-15 | 阿达瓦克医疗有限公司 | Irrigation and aspiration devices and methods |
EP2429624B1 (en) | 2009-05-15 | 2014-04-02 | Intersect ENT, Inc. | A combination of an expandable device and a delivery device. |
JP5805634B2 (en) | 2009-06-08 | 2015-11-04 | アムニクス オペレーティング インコーポレイテッド | Growth hormone polypeptides and methods of making and using the same |
EP2440251A4 (en) | 2009-06-09 | 2013-01-16 | Defyrus Inc | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
WO2011069010A2 (en) | 2009-12-02 | 2011-06-09 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
US20110139163A1 (en) * | 2009-12-15 | 2011-06-16 | Hillila David J | Vibration apparatus for stimulating paranasal sinuses |
FR2954707B1 (en) * | 2009-12-28 | 2016-01-08 | Diffusion Tech Francaise Sarl | ORAL AEROSOL DELIVERY DEVICE USING A RHINOPHARYNGEAL, NASAL OR NASOSINUSIAN VISION |
JP3193069U (en) | 2010-09-02 | 2014-09-18 | シプノーズ リミテッド | Nasal administration device |
EP2431732A1 (en) * | 2010-09-21 | 2012-03-21 | Dow Global Technologies LLC | Linking on-line analysis and tracer technology |
AU2012212866B2 (en) | 2011-01-31 | 2016-09-15 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
US20120204887A1 (en) * | 2011-02-11 | 2012-08-16 | Connor Robert A | Adjustable Snore-Attenuating Pressure (ASAP) |
CA2828884C (en) | 2011-03-03 | 2021-04-27 | Impel Neuropharma, Inc. | Nasal drug delivery device |
BR112013028572B8 (en) | 2011-05-09 | 2022-10-25 | Impel Neuropharma Inc | NOZZLES FOR NASAL DRUG DELIVERY |
US8944052B2 (en) * | 2011-05-26 | 2015-02-03 | Ivan Osorio | Apparatus and methods for delivery of therapeutic agents to mucous or serous membrane |
MY168354A (en) | 2011-07-18 | 2018-10-31 | Rhinosystems Inc | Nasal irrigation device and system with faux collapsible cartridge element |
GB2496684A (en) * | 2011-11-21 | 2013-05-22 | Adi Wallach | Breathing biofeedback device optionally comprising inhalable substance dispenser and breathing feedback methods |
WO2013090999A1 (en) * | 2011-12-19 | 2013-06-27 | Resmed Limited | Respiratory treatment system including physiological sensors |
KR102008190B1 (en) | 2012-02-15 | 2019-08-07 | 바이오버라티브 테라퓨틱스 인크. | Recombinant factor viii proteins |
ES2935489T3 (en) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Factor VIII compositions and methods of preparation and use thereof |
CA2869787C (en) | 2012-06-08 | 2021-11-23 | Alkermes, Inc. | Ligands modified by circular permutation as agonists and antagonists |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
EP2866867B1 (en) * | 2012-06-28 | 2017-05-31 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
DE202012008892U1 (en) * | 2012-09-14 | 2013-12-16 | 5med GmbH | nasal applicator |
WO2014053592A1 (en) | 2012-10-03 | 2014-04-10 | Proponent Biotech Gmbh | Esters of short chains fatty acids for use in the treatment of immunogenic disorders |
US9433724B2 (en) * | 2012-10-30 | 2016-09-06 | Preva, Llc. | Irrigation assembly |
US10478547B2 (en) | 2012-10-30 | 2019-11-19 | Preva, Llc. | Irrigation assembly |
US11179513B2 (en) | 2012-10-30 | 2021-11-23 | Preva, Llc | Irrigation assembly |
US9795756B2 (en) | 2012-12-04 | 2017-10-24 | Mallinckrodt Hospital Products IP Limited | Cannula for minimizing dilution of dosing during nitric oxide delivery |
SI2928531T1 (en) | 2012-12-04 | 2017-07-31 | Ino Therapeutics LLC Perryville III Corporate Park | Cannula for minimizing dilution of dosing during nitric oxide delivery |
WO2014093277A1 (en) | 2012-12-11 | 2014-06-19 | The Mclean Hospital Corporation | Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders |
EP2961426B1 (en) | 2013-02-26 | 2019-10-30 | Baxalta GmbH | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
WO2014164897A2 (en) * | 2013-03-11 | 2014-10-09 | Collins John R | Inhalator device and method |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
EP3636227A1 (en) | 2013-03-14 | 2020-04-15 | Intersect ENT, Inc. | Systems and devices for treating a sinus condition |
US10493226B2 (en) | 2013-03-15 | 2019-12-03 | Seedlings Life Science Ventures, Llc | System and assembly for inflating and monitoring pressure within a retaining cuff |
USD732658S1 (en) | 2013-03-26 | 2015-06-23 | Pediatric Innovations USA, LLC | Nasal device with airplane wings |
USD732659S1 (en) | 2013-03-26 | 2015-06-23 | Pediatric Innovations USA, LLC | Car-shaped nasal device |
WO2014179228A1 (en) | 2013-04-28 | 2014-11-06 | Impel Neuropharma Inc. | Medical unit dose container |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
CN103405835B (en) * | 2013-07-31 | 2015-03-04 | 解秀丽 | Integrated medical vaporizer |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP2868334B1 (en) * | 2013-11-05 | 2017-01-11 | Benedict Gerber | Nasal spray |
US10265462B2 (en) | 2014-02-13 | 2019-04-23 | Preva, Llc. | Nasal irrigation assembly and system |
US11311706B2 (en) | 2014-02-13 | 2022-04-26 | Preva, Llc | Nasal irrigation assembly and system |
US9289547B2 (en) | 2014-02-13 | 2016-03-22 | Preva, Llc | Nasal irrigation assembly and system |
US11077236B2 (en) * | 2014-12-15 | 2021-08-03 | Genicon, Inc. | Powered lavage handle and associated use therefore |
FR3031313A1 (en) * | 2015-01-05 | 2016-07-08 | Air Liquide Medical Systems | RESPIRATORY ASSISTING APPARATUS WITH DETECTION OF ALL TURBINE STOP |
US20160199599A1 (en) * | 2015-01-13 | 2016-07-14 | Bhl Patent Holdings Llc | Nasal Delivery Device and Methods of Use |
NZ706864A (en) | 2015-04-09 | 2016-07-29 | Aft Pharmaceuticals Ltd | A nasal medication delivery device |
EA201890423A1 (en) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION |
CN108601916B (en) | 2015-09-10 | 2021-07-09 | 英倍尔药业股份有限公司 | In-line nasal delivery device |
US10206432B2 (en) * | 2015-12-24 | 2019-02-19 | Altria Client Services Llc | Flexible aerosol-generating devices |
WO2017108452A1 (en) | 2015-12-24 | 2017-06-29 | Philip Morris Products S.A. | Flexible aerosol-generating devices |
EP3411102B1 (en) | 2016-02-04 | 2021-08-25 | IP Med, Inc. | Medicament delivery device |
GB201619637D0 (en) | 2016-11-21 | 2017-01-04 | Pekna Marcela And Pekny Milos And Stokowska Anna | C3a receptor agonists |
DE102017004224A1 (en) * | 2016-12-13 | 2018-11-08 | Drägerwerk AG & Co. KGaA | Nasal cannula for high-flow ventilation |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
CN107376063B (en) * | 2017-07-04 | 2020-08-21 | 浙江医尔仁医疗科技有限公司 | Chinese and western medicine targeted atomization device |
IL254328B (en) | 2017-09-04 | 2022-01-01 | Jerasi Meir | An improved apparatus for enhanced nostril breathing |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
CN115445033A (en) | 2017-10-09 | 2022-12-09 | 珍珠治疗公司 | Drug delivery systems and related methods |
US11395887B2 (en) | 2017-11-21 | 2022-07-26 | Impel Pharmaceuticals Inc. | Intranasal device with inlet interface |
JP7191099B2 (en) | 2017-11-21 | 2022-12-16 | インペル ファーマシューティカルズ インコーポレイテッド | intranasal device with dip tube |
EP4147699A1 (en) | 2018-01-05 | 2023-03-15 | Impel Pharmaceuticals Inc. | Intranasal delivery of dihydroergotamine by precision olfactory device |
BR112020013750A8 (en) | 2018-01-05 | 2022-10-18 | Impel Neuropharma Inc | INTRANASAL DISPENSE OF OLANZAPINE BY PRECISION OLFATIVE DEVICE |
EA039533B1 (en) * | 2018-03-07 | 2022-02-08 | Перл Терапьютикс, Инк. | Drug delivery device |
KR102125502B1 (en) | 2018-03-27 | 2020-06-22 | 대전대학교 산학협력단 | Odor evaluation device for multi sample suction module |
WO2020005910A1 (en) * | 2018-06-28 | 2020-01-02 | Sandler Scientific, Llc | Sino-nasal rinse delivery device with agitation, flow-control and integrated medication management system |
EP3823607A4 (en) | 2018-07-19 | 2022-04-06 | Impel NeuroPharma Inc. | Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease |
CN109674495B (en) * | 2018-08-01 | 2021-02-26 | 浙江三创生物科技有限公司 | Method and apparatus for administering a drug |
US20220296825A1 (en) * | 2018-10-04 | 2022-09-22 | Optinose As | Exhalation delivery system for and method of treating sinus disease |
BR112021013244A8 (en) | 2019-01-03 | 2022-10-18 | Impel Neuropharma Inc | NASAL DRUG DELIVERY DEVICE |
CN109939326B (en) * | 2019-04-18 | 2023-10-31 | 首都医科大学附属北京安贞医院 | Olfactory training device based on expiratory pressure |
BR112021023049A8 (en) | 2019-05-17 | 2022-10-18 | Impel Neuropharma Inc | SINGLE USE NASAL DISPENSING DEVICE |
CA3142934A1 (en) | 2019-06-09 | 2020-12-17 | Kblv Medical, Llc | Device and system for remote regulation and monitoring of drug delivery and method of same |
EP4093467A4 (en) * | 2020-01-22 | 2024-04-10 | Univ Virginia Commonwealth | Dry powder inhalers and interfaces for improved aerosol delivery to children |
US11207057B1 (en) | 2020-08-07 | 2021-12-28 | Cyrano Medical, Inc. | Nasopharyngeal sample collection devices and methods |
CN113318304B (en) * | 2021-05-25 | 2023-01-31 | 新乡医学院第一附属医院 | Nasal cavity local circulation atomizer and nasal cavity atomization treatment method |
CN113546290A (en) * | 2021-08-19 | 2021-10-26 | 南京澳博工业智能科技研究院有限公司 | Nasal cavity drug delivery device |
CN115282412B (en) * | 2022-01-14 | 2023-08-25 | 温州医科大学 | Drug delivery device for entering blood circulation through nasal cavity and application method thereof |
CN115282411A (en) * | 2022-01-14 | 2022-11-04 | 温州医科大学 | Delivery system for delivering drugs into the brain using the nasal olfactory region and method of use thereof |
CN115300726A (en) * | 2022-01-14 | 2022-11-08 | 温州医科大学 | Special nasal delivery system and application method thereof |
DE102022000297A1 (en) | 2022-01-26 | 2023-07-27 | Florian Matl | DEVICE FOR ADMINISTRATION OF AN AEROSOL TO THE NOSES, ACTIVATION DEVICE AND AEROSOL GENERATION DEVICE |
WO2023165486A1 (en) * | 2022-03-01 | 2023-09-07 | 园丁医疗科技(苏州)有限公司 | Electric nasal irrigator with oral exhalation sensing |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1873160A (en) * | 1929-02-08 | 1932-08-23 | Harold V Sturtevant | Breathing apparatus |
GB408856A (en) * | 1933-08-14 | 1934-04-19 | Wietske Van Seters Bosch | Improvements in and relating to inhalers |
US2470297A (en) * | 1947-09-04 | 1949-05-17 | Abbott Lab | Inhalator |
US4919128A (en) * | 1988-08-26 | 1990-04-24 | University Technologies International Inc. | Nasal adaptor device and seal |
EP0634186A2 (en) * | 1993-06-18 | 1995-01-18 | Resmed Limited | Facial breathing mask |
WO1998053869A1 (en) * | 1997-05-27 | 1998-12-03 | Direct-Haler A/S | Inhaler for powdered medicaments |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US39678A (en) | 1863-08-25 | Improvement in powder-injectors | ||
US419942A (en) | 1890-01-21 | Insufflator | ||
US605436A (en) | 1898-06-07 | Inhaler | ||
US429321A (en) | 1890-06-03 | Inhaler | ||
US642748A (en) * | 1899-02-23 | 1900-02-06 | Arthur Manners | Inhaler. |
US658436A (en) | 1900-05-28 | 1900-09-25 | Hans Hennerich Groth | Insufflator. |
US707445A (en) | 1902-04-10 | 1902-08-19 | John Howard Mcculloch | Inhaler. |
US723738A (en) | 1902-06-05 | 1903-03-24 | August K Schulte | Inhaler. |
US746749A (en) | 1903-03-18 | 1903-12-15 | George E Seidel | Nasal medicator. |
US781428A (en) * | 1904-07-28 | 1905-01-31 | Sheridan J Hutchins | Inhaler, injector, and medicator. |
US794641A (en) | 1905-03-06 | 1905-07-11 | Alfred H Ramey | Inhaler. |
US867827A (en) * | 1906-05-14 | 1907-10-08 | John Howard Mcculloch | Inhaler. |
US902832A (en) * | 1907-09-20 | 1908-11-03 | Edward F Philbrook | Inhaler. |
US1375325A (en) | 1920-06-29 | 1921-04-19 | Schaefer William Henry | Inhaler |
US1540274A (en) | 1924-03-28 | 1925-06-02 | William J Moore | Nasal inhaler |
US2021332A (en) | 1931-11-28 | 1935-11-19 | Silten Ernst | Inhalation apparatus |
US2086588A (en) | 1935-11-18 | 1937-07-13 | Joseph J Tobin | Vaporizing applicator |
US2223611A (en) | 1939-05-22 | 1940-12-03 | Richard E Gross | Syringe |
US2693805A (en) | 1947-03-08 | 1954-11-09 | George V Taplin | Apparatus for administering therapeutic agents |
US2546214A (en) * | 1947-03-17 | 1951-03-27 | Harold E Curry | Applicator |
US2945495A (en) * | 1958-03-05 | 1960-07-19 | Waldo R Griffin | Nasal irrigator |
US3605738A (en) * | 1969-06-20 | 1971-09-20 | Paul J Ciranna | Medicinal spray device |
US3847145A (en) * | 1973-04-13 | 1974-11-12 | M Grossan | Nasal irrigation system |
US3888252A (en) | 1974-01-23 | 1975-06-10 | Anthony J Side | Powder inhaler |
US3949939A (en) * | 1975-03-26 | 1976-04-13 | Smithkline Corporation | Metered spray device |
US4216768A (en) | 1978-03-23 | 1980-08-12 | Whitfield Jack | Device for inhaling powdered substance |
US4265236A (en) | 1980-03-31 | 1981-05-05 | Pacella Angelo M | Portable inhalator device |
DE3018691C2 (en) | 1980-05-16 | 1982-10-28 | Gerhard 7166 Sulzbach-Laufen Hansen | Device for self-blowing a powdery or liquid substance into a body opening |
US4325366A (en) * | 1980-07-07 | 1982-04-20 | Tabor Carl J | Valve and method for use with a tracheotomy tube |
DE3345722A1 (en) | 1983-12-17 | 1985-06-27 | Boehringer Ingelheim KG, 6507 Ingelheim | INHALATOR |
FI69962C (en) | 1983-12-28 | 1986-09-12 | Huhtamaeki Oy | INHALATIONSANORDNING |
US4660555A (en) | 1984-09-21 | 1987-04-28 | Payton Hugh W | Oxygen delivery and administration system |
US4674494A (en) | 1985-05-10 | 1987-06-23 | The Kendall Company | Humidifying device |
US4782832A (en) * | 1987-07-30 | 1988-11-08 | Puritan-Bennett Corporation | Nasal puff with adjustable sealing means |
US5046493A (en) | 1988-02-16 | 1991-09-10 | James Kropkowski | Nasal dispenser |
GB8810898D0 (en) | 1988-05-09 | 1988-06-15 | Bespak Plc | Improvements in dispensing apparatus |
FR2638361B1 (en) | 1988-10-28 | 1991-01-11 | Diffusion Tech Francaise Sarl | NARINARY MOUTHPIECE ADAPTABLE TO ALL MEDICAL APPLIANCES OF THE NEBULIZER TYPE AND OTHER |
AU643435B2 (en) | 1989-04-28 | 1993-11-18 | Riker Laboratories, Inc. | Dry powder inhalation device |
CA2003895C (en) * | 1989-11-16 | 1999-03-30 | Jean-Pierre Robitaille | Filtre intra-nasal |
US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
EP0563120B1 (en) * | 1990-12-17 | 1997-10-01 | Minnesota Mining And Manufacturing Company | Inhaler |
US5477852A (en) * | 1991-10-29 | 1995-12-26 | Airways Ltd., Inc. | Nasal positive airway pressure apparatus and method |
US5373841A (en) | 1992-02-04 | 1994-12-20 | Kyllonen; David M. | Self-operated nasal humidifier |
US5222491A (en) * | 1992-05-29 | 1993-06-29 | Thomas Samuel D | Temporary patient ventilator |
US5284133A (en) * | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
GB2270293A (en) | 1992-09-05 | 1994-03-09 | Medix Ltd | Drug dispensing system |
FR2696080B1 (en) | 1992-09-30 | 1994-12-23 | Jesus Covarrubias | Cigarette filter for administration of taurine by inhalation. |
US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
EP0683648B1 (en) | 1993-02-12 | 1998-09-16 | Minnesota Mining And Manufacturing Company | Aerosol delivery apparatus |
US5437267A (en) * | 1993-08-03 | 1995-08-01 | Weinstein; Allan | Device for delivering aerosol to the nasal membranes and method of use |
US5375593A (en) * | 1994-02-10 | 1994-12-27 | Press; John R. | Oxygenating pacifier |
GB9415722D0 (en) | 1994-08-03 | 1994-09-21 | Fxk Patents Ltd | Breathing equipment |
TR199700669T1 (en) | 1995-01-23 | 1998-02-21 | Direct-Haler A/S | �nhalat�r. |
US5653961A (en) * | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5850833A (en) * | 1995-05-22 | 1998-12-22 | Kotliar; Igor K. | Apparatus for hypoxic training and therapy |
JP3434396B2 (en) | 1995-06-30 | 2003-08-04 | 株式会社日立ユニシアオートモティブ | Nasal administration device |
SE506208C2 (en) | 1995-07-05 | 1997-11-24 | Aerocrine Systems Kb | Device for collecting gas from the upper respiratory tract and delivering this gas to the inhalation air in a respirator |
US5692496A (en) * | 1995-08-02 | 1997-12-02 | Innovative Devices, Llc | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
SE9502800D0 (en) | 1995-08-10 | 1995-08-10 | Astra Ab | Disposable inhalers |
US5848587A (en) * | 1995-09-21 | 1998-12-15 | Medi-Nuclear Corporation, Inc. | Aerosol medication delivery system |
US5669378A (en) | 1995-12-21 | 1997-09-23 | Pera; Ivo | Inhaling device |
US5797392C1 (en) * | 1996-01-22 | 2001-01-09 | Direct Haler As | Inhaler |
US5694920A (en) * | 1996-01-25 | 1997-12-09 | Abrams; Andrew L. | Inhalation device |
EP0965084A1 (en) | 1996-03-21 | 1999-12-22 | MPATH Interactive Inc. | Network match maker for selecting clients based on attributes of servers and communication links |
FR2747311B1 (en) * | 1996-04-10 | 1998-08-14 | Pf Medicament | POWDER AND COMPRESSED AIR INHALER |
US6074673A (en) | 1996-04-22 | 2000-06-13 | Guillen; Manuel | Slow-release, self-absorbing, drug delivery system |
US5957125A (en) * | 1996-11-05 | 1999-09-28 | Medical Safety Products, Inc. | Apparatus for indicating proper orientation for oral and nasal inhalers |
US5752510A (en) | 1996-11-14 | 1998-05-19 | Goldstein; Joseph | Nasal and oral air passageway delivery management apparatus |
US5829435A (en) * | 1997-02-24 | 1998-11-03 | Aradigm Corporation | Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles |
US6013623A (en) * | 1997-02-27 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | Use of heme-peptides to prevent or retard disease associated with oxidative stress |
US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US5937852A (en) * | 1997-04-08 | 1999-08-17 | The Board Of Regents Of The University Of Texas System | Apparatus for induction of inhaled pharmacological agent by a pediatric patient |
US5865172A (en) * | 1997-04-08 | 1999-02-02 | The Board Of Regents Of The University Of Texas System | Method and apparatus for induction of inhaled pharmacological agent by a pediatric patient |
US6125846A (en) | 1997-05-16 | 2000-10-03 | Datex-Ohmeda, Inc. | Purge system for nitric oxide administration apparatus |
US5904140A (en) | 1997-06-24 | 1999-05-18 | Mcgoogan; Elizabeth M. | Medical pacifier |
US6182660B1 (en) * | 1998-02-22 | 2001-02-06 | William J. Hopper | Non-invasive sinus pain relieving assembly |
US6125844A (en) * | 1998-04-30 | 2000-10-03 | Westwood Biomedical | Portable oxygen based drug delivery system |
US6145503A (en) * | 1998-07-13 | 2000-11-14 | Smith; Ronnie | Olfactory activator |
GB0121568D0 (en) * | 2001-09-06 | 2001-10-24 | Optinose As | Nasal delivery device |
GB0114272D0 (en) | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
KR100692422B1 (en) * | 1999-03-03 | 2007-03-09 | 옵티노즈 에이에스 | Nasal delivery device |
EP1110572A1 (en) * | 1999-12-24 | 2001-06-27 | Gert F. Kölbel | Inhalation device |
GB0015309D0 (en) * | 2000-06-21 | 2000-08-16 | Djupesland Per G | Apparatus |
ZA200306564B (en) * | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
GB0207422D0 (en) | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
GB0215270D0 (en) * | 2002-07-02 | 2002-08-14 | Optinose As | Nasal devices |
GB0215904D0 (en) * | 2002-07-09 | 2002-08-21 | Team Holdings Uk Ltd | Drug delivery system and method |
GB0311570D0 (en) * | 2003-05-20 | 2003-06-25 | Optinose As | Delivery device and method |
GB0319119D0 (en) * | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
GB0320171D0 (en) * | 2003-08-28 | 2003-10-01 | Optinose As | Delivery devices |
GB0420513D0 (en) * | 2004-09-15 | 2004-10-20 | Optinose As | Powder delivery devices |
GB0503738D0 (en) | 2005-02-23 | 2005-03-30 | Optinose As | Powder delivery devices |
US8171929B2 (en) | 2006-02-14 | 2012-05-08 | Optinose As | Delivery device and method |
GB0602980D0 (en) | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
GB0604319D0 (en) | 2006-03-03 | 2006-04-12 | Optinose As | Nasal delivery |
GB0604444D0 (en) | 2006-03-06 | 2006-04-12 | Optinose As | Nasal devices |
GB0605799D0 (en) | 2006-03-23 | 2006-05-03 | Optinose As | Nasal delivery devices |
GB2437488A (en) | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
GB2440316A (en) | 2006-07-25 | 2008-01-30 | Optinose As | Nasal inhaler with scrubber |
-
2000
- 2000-03-03 KR KR1020017011177A patent/KR100692422B1/en not_active IP Right Cessation
- 2000-03-03 CN CN008045585A patent/CN1217712C/en not_active Expired - Fee Related
- 2000-03-03 DE DE60045216T patent/DE60045216D1/en not_active Expired - Lifetime
- 2000-03-03 JP JP2000602333A patent/JP4543553B2/en not_active Expired - Lifetime
- 2000-03-03 DK DK01124194T patent/DK1180378T3/en active
- 2000-03-03 DK DK00906570T patent/DK1161274T3/en active
- 2000-03-03 CN CNA2005100825927A patent/CN1736502A/en active Pending
- 2000-03-03 ID ID20011888A patent/ID30286A/en unknown
- 2000-03-03 DE DE60017099T patent/DE60017099T2/en not_active Expired - Lifetime
- 2000-03-03 DK DK04030887T patent/DK1555038T3/en active
- 2000-03-03 EP EP20010124194 patent/EP1180378B8/en not_active Expired - Lifetime
- 2000-03-03 BR BRPI0008650-9A patent/BR0008650B1/en not_active IP Right Cessation
- 2000-03-03 AU AU28227/00A patent/AU766410B2/en not_active Ceased
- 2000-03-03 NZ NZ514442A patent/NZ514442A/en not_active IP Right Cessation
- 2000-03-03 WO PCT/IB2000/000273 patent/WO2000051672A1/en active IP Right Grant
- 2000-03-03 AT AT04030887T patent/ATE514445T1/en not_active IP Right Cessation
- 2000-03-03 SI SI200031064T patent/SI1180378T1/en unknown
- 2000-03-03 CA CA002364009A patent/CA2364009C/en not_active Expired - Lifetime
- 2000-03-03 IL IL14498800A patent/IL144988A0/en unknown
- 2000-03-03 EP EP20100011952 patent/EP2332603B1/en not_active Expired - Lifetime
- 2000-03-03 AT AT00906570T patent/ATE285810T1/en active
- 2000-03-03 ES ES10011951.0T patent/ES2600357T3/en not_active Expired - Lifetime
- 2000-03-03 PL PL350220A patent/PL203959B1/en not_active IP Right Cessation
- 2000-03-03 ES ES00906570T patent/ES2235836T3/en not_active Expired - Lifetime
- 2000-03-03 PT PT00906570T patent/PT1161274E/en unknown
- 2000-03-03 ES ES10011952T patent/ES2439274T3/en not_active Expired - Lifetime
- 2000-03-03 PL PL387459A patent/PL206121B1/en not_active IP Right Cessation
- 2000-03-03 EP EP16180246.7A patent/EP3124067A3/en not_active Withdrawn
- 2000-03-03 PT PT01124194T patent/PT1180378E/en unknown
- 2000-03-03 SI SI200030636T patent/SI1161274T1/en unknown
- 2000-03-03 TR TR200102563T patent/TR200102563T2/en unknown
- 2000-03-03 GB GB0005254A patent/GB2349092B/en not_active Expired - Lifetime
- 2000-03-03 US US09/700,532 patent/US6715485B1/en not_active Expired - Lifetime
- 2000-03-03 EP EP20040030887 patent/EP1555038B1/en not_active Expired - Lifetime
- 2000-03-03 MX MXPA01008849A patent/MXPA01008849A/en active IP Right Grant
- 2000-03-03 EP EP00906570A patent/EP1161274B1/en not_active Expired - Lifetime
- 2000-03-03 AT AT01124194T patent/ATE487506T1/en active
- 2000-03-03 EP EP10011951.0A patent/EP2340865B1/en not_active Expired - Lifetime
-
2001
- 2001-08-20 IL IL144988A patent/IL144988A/en not_active IP Right Cessation
- 2001-08-28 NO NO20014182A patent/NO20014182L/en not_active Application Discontinuation
-
2002
- 2002-02-04 HK HK02100833.9A patent/HK1039459B/en not_active IP Right Cessation
- 2002-02-04 HK HK02106029.0A patent/HK1044492A1/en unknown
-
2004
- 2004-03-30 US US10/813,326 patent/US8327844B2/en not_active Expired - Lifetime
-
2006
- 2006-06-02 US US11/445,993 patent/US9119932B2/en not_active Expired - Lifetime
- 2006-06-02 US US11/445,812 patent/US8555877B2/en not_active Expired - Lifetime
- 2006-06-02 US US11/446,424 patent/US9072857B2/en not_active Expired - Fee Related
- 2006-06-02 US US11/445,994 patent/US8555878B2/en not_active Expired - Fee Related
-
2010
- 2010-05-17 JP JP2010113331A patent/JP5253452B2/en not_active Expired - Lifetime
-
2011
- 2011-02-10 CY CY20111100160T patent/CY1111201T1/en unknown
-
2015
- 2015-05-29 US US14/725,602 patent/US20160095993A1/en not_active Abandoned
- 2015-12-22 US US14/978,230 patent/US20160250408A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1873160A (en) * | 1929-02-08 | 1932-08-23 | Harold V Sturtevant | Breathing apparatus |
GB408856A (en) * | 1933-08-14 | 1934-04-19 | Wietske Van Seters Bosch | Improvements in and relating to inhalers |
US2470297A (en) * | 1947-09-04 | 1949-05-17 | Abbott Lab | Inhalator |
US4919128A (en) * | 1988-08-26 | 1990-04-24 | University Technologies International Inc. | Nasal adaptor device and seal |
EP0634186A2 (en) * | 1993-06-18 | 1995-01-18 | Resmed Limited | Facial breathing mask |
WO1998053869A1 (en) * | 1997-05-27 | 1998-12-03 | Direct-Haler A/S | Inhaler for powdered medicaments |
Cited By (284)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8511303B2 (en) | 1999-03-03 | 2013-08-20 | Optinose As | Nasal delivery devices |
US7836883B2 (en) | 1999-07-12 | 2010-11-23 | Capnia, Inc. | Methods for treating rhinitis and conjunctivitis |
US7827986B2 (en) | 1999-07-12 | 2010-11-09 | Capnia, Inc. | Methods for treating jaw pain |
US7017573B1 (en) | 1999-07-12 | 2006-03-28 | Capnia, Incorporated | Methods and apparatus for relieving headaches, rhinitis and other common ailments |
US7748379B2 (en) | 1999-07-12 | 2010-07-06 | Capnia, Inc. | Methods and apparatus for relieving headaches, rhinitis and other common ailments |
US7845347B2 (en) | 1999-07-12 | 2010-12-07 | Capnia, Inc. | Methods for treating headaches |
US7845348B2 (en) | 1999-07-12 | 2010-12-07 | Capnia, Inc. | Methods for treating trigeminal neuralgia |
US8464711B2 (en) | 1999-07-12 | 2013-06-18 | Capnia, Inc. | Methods for treating headaches |
US8096968B2 (en) | 1999-11-08 | 2012-01-17 | Capnia, Inc. | Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces |
US6959708B1 (en) | 1999-11-08 | 2005-11-01 | Capnia, Incorporated | Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments |
US8398580B2 (en) | 1999-11-08 | 2013-03-19 | Capnia, Inc. | Methods and apparatus for treating rhinitis |
US7841337B2 (en) | 2000-11-15 | 2010-11-30 | Optinose As | Breath-actuated nasal delivery device |
EP2570146A1 (en) | 2001-02-26 | 2013-03-20 | Optinose AS | Nasal devices |
GB2374807A (en) * | 2001-02-26 | 2002-10-30 | Optinose As | Nasal delivery devices comprising a delivery prevention mechanism |
WO2002068029A2 (en) * | 2001-02-26 | 2002-09-06 | Optinose As | Nasal delivery devices |
US7347201B2 (en) | 2001-02-26 | 2008-03-25 | Optinose As | Nasal delivery devices |
JP2009034534A (en) * | 2001-02-26 | 2009-02-19 | Optinose As | Nasal devices |
WO2002068030A3 (en) * | 2001-02-26 | 2003-02-06 | Optinose As | Nasal devices |
WO2002068029A3 (en) * | 2001-02-26 | 2002-12-12 | Optinose As | Nasal delivery devices |
WO2002068031A3 (en) * | 2001-02-26 | 2002-12-12 | Optinose As | Nasal delivery devices |
US8522778B2 (en) | 2001-02-26 | 2013-09-03 | Optinose As | Nasal devices |
US8596278B2 (en) | 2001-02-26 | 2013-12-03 | Optinose As | Nasal devices |
US7740014B2 (en) | 2001-02-26 | 2010-06-22 | Optinose As | Nasal devices |
WO2002068032A3 (en) * | 2001-02-26 | 2003-05-22 | Optinose As | Nasal devices |
GB2374538B (en) * | 2001-02-26 | 2005-02-23 | Optinose As | Nasal devices |
GB2374808B (en) * | 2001-02-26 | 2005-02-23 | Optinose As | Nasal devices |
GB2374808A (en) * | 2001-02-26 | 2002-10-30 | Optinose As | Nasal delivery devices comprising a flow resistor |
US7543581B2 (en) | 2001-02-26 | 2009-06-09 | Optinose As | Nasal devices |
GB2374537B (en) * | 2001-02-26 | 2005-04-13 | Optinose As | Nasal devices |
GB2374538A (en) * | 2001-02-26 | 2002-10-23 | Optinose As | Breath actuated nasal delivery devices |
WO2002068031A2 (en) | 2001-02-26 | 2002-09-06 | Optinose As | Nasal delivery devices |
WO2002068032A2 (en) | 2001-02-26 | 2002-09-06 | Optinose As | Nasal devices |
WO2002068030A2 (en) * | 2001-02-26 | 2002-09-06 | Optinose As | Nasal devices |
GB2374807B (en) * | 2001-02-26 | 2005-12-07 | Optinose As | Nasal devices |
EP1410820A3 (en) * | 2001-06-12 | 2007-08-22 | Optinose AS | Nasal delivery devices |
JP2009261976A (en) * | 2001-06-12 | 2009-11-12 | Optinose As | Nasal delivery device |
JP4551965B2 (en) * | 2001-06-12 | 2010-09-29 | オプティノーズ アズ | Nasal device |
EP3100757A1 (en) | 2001-06-12 | 2016-12-07 | Optinose AS | Nasal devices |
CN100428966C (en) * | 2001-06-12 | 2008-10-29 | 奥普蒂诺斯公司 | Nasal delivery devices |
JP2010179168A (en) * | 2001-06-12 | 2010-08-19 | Optinose As | Nasal delivery device |
JP2009261977A (en) * | 2001-06-12 | 2009-11-12 | Optinose As | Nasal delivery device |
EP1410820A2 (en) | 2001-06-12 | 2004-04-21 | Optinose AS | Nasal delivery devices |
EP1407795A2 (en) | 2001-06-12 | 2004-04-14 | Optinose AS | Nasal delivery devices |
EP1407795A3 (en) * | 2001-06-12 | 2007-08-22 | Optinose AS | Nasal delivery devices |
US7975690B2 (en) | 2001-06-12 | 2011-07-12 | Optinose As | Nasal devices |
US9205208B2 (en) | 2001-06-12 | 2015-12-08 | Optinose As | Nasal devices |
EP1399203A1 (en) * | 2001-06-12 | 2004-03-24 | Optinose AS | Nasal drug delivery devices |
EP1399203B1 (en) * | 2001-06-12 | 2015-09-16 | Optinose AS | Nasal drug delivery devices |
JP2013099535A (en) * | 2001-06-12 | 2013-05-23 | Optinose As | Transnasal device |
WO2003000310A2 (en) | 2001-06-12 | 2003-01-03 | Optinose As | Nasal devices |
US20120006323A1 (en) * | 2001-06-12 | 2012-01-12 | Optinose As | Nasal devices |
WO2003020350A1 (en) | 2001-09-06 | 2003-03-13 | Optinose As | Nasal delivery device |
US20080163874A1 (en) * | 2001-09-06 | 2008-07-10 | Optinose As | Nasal delivery device |
US8146589B2 (en) | 2002-03-28 | 2012-04-03 | Optinose As | Nasal devices |
WO2003082393A1 (en) * | 2002-03-28 | 2003-10-09 | Optinose As | Nasal devices |
JP2010012291A (en) * | 2002-03-28 | 2010-01-21 | Optinose As | Nasal delivery device |
WO2003084591A1 (en) | 2002-04-04 | 2003-10-16 | Optinose As | Nasal devices |
WO2003090812A2 (en) * | 2002-04-25 | 2003-11-06 | Optinose As | Nasal devices |
WO2003090812A3 (en) * | 2002-04-25 | 2003-12-31 | Optinose As | Nasal devices |
US7854227B2 (en) | 2002-04-25 | 2010-12-21 | Optinose As | Nasal devices |
US9522243B2 (en) | 2002-07-02 | 2016-12-20 | Optinose As | Nasal devices |
US8047202B2 (en) | 2002-07-02 | 2011-11-01 | Optinose As | Nasal devices |
US7481218B2 (en) | 2002-07-02 | 2009-01-27 | Optinose As | Nasal devices |
WO2004020029A1 (en) * | 2002-08-27 | 2004-03-11 | Pari GmbH Spezialisten für effektive Inhalation | Therapeutic aerosol device |
US7980247B2 (en) | 2002-08-27 | 2011-07-19 | Pari Gmbh Spezialisten Fuer Effektive Inhalation | Therapeutic aerosol device |
WO2004060433A3 (en) * | 2003-01-02 | 2005-04-28 | Optinose As | Delivery devices |
WO2004060433A2 (en) | 2003-01-02 | 2004-07-22 | Optinose As | Delivery devices |
US10286164B2 (en) | 2003-05-20 | 2019-05-14 | Optinose As | Delivery device and method |
US9566402B2 (en) | 2003-05-20 | 2017-02-14 | Optinose As | Delivery Device and Method |
WO2004103447A2 (en) * | 2003-05-20 | 2004-12-02 | Optinose As | Delivery device and method |
WO2004103447A3 (en) * | 2003-05-20 | 2005-02-17 | Optinose As | Delivery device and method |
WO2005016423A3 (en) * | 2003-08-14 | 2005-07-07 | Optinose As | Delivery devices |
US7784460B2 (en) | 2003-08-14 | 2010-08-31 | Optinose As | Delivery devices |
WO2005016423A2 (en) * | 2003-08-14 | 2005-02-24 | Optinose As | Delivery devices |
US9452272B2 (en) | 2003-08-14 | 2016-09-27 | Optinose As | Delivery devices |
WO2005021059A2 (en) | 2003-08-28 | 2005-03-10 | Optinose As | Delivery devices |
US10737045B2 (en) | 2003-08-28 | 2020-08-11 | Optinose As | Delivery devices |
WO2005021059A3 (en) * | 2003-08-28 | 2005-08-04 | Optinose As | Delivery devices |
US8800555B2 (en) | 2003-08-28 | 2014-08-12 | Optinose As | Delivery devices |
US9610428B2 (en) | 2004-04-21 | 2017-04-04 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US8961398B2 (en) | 2004-04-21 | 2015-02-24 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US9167961B2 (en) | 2004-04-21 | 2015-10-27 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
US9220879B2 (en) | 2004-04-21 | 2015-12-29 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US10695080B2 (en) | 2004-04-21 | 2020-06-30 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat |
US10702295B2 (en) | 2004-04-21 | 2020-07-07 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
US10779752B2 (en) | 2004-04-21 | 2020-09-22 | Acclarent, Inc. | Guidewires for performing image guided procedures |
US10806477B2 (en) | 2004-04-21 | 2020-10-20 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US10631756B2 (en) | 2004-04-21 | 2020-04-28 | Acclarent, Inc. | Guidewires for performing image guided procedures |
US9107574B2 (en) | 2004-04-21 | 2015-08-18 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US10856727B2 (en) | 2004-04-21 | 2020-12-08 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US10874838B2 (en) | 2004-04-21 | 2020-12-29 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US10500380B2 (en) | 2004-04-21 | 2019-12-10 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US10492810B2 (en) | 2004-04-21 | 2019-12-03 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat |
US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US10441758B2 (en) | 2004-04-21 | 2019-10-15 | Acclarent, Inc. | Frontal sinus spacer |
US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US11019989B2 (en) | 2004-04-21 | 2021-06-01 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
US11020136B2 (en) | 2004-04-21 | 2021-06-01 | Acclarent, Inc. | Deflectable guide catheters and related methods |
US9241834B2 (en) | 2004-04-21 | 2016-01-26 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US11065061B2 (en) | 2004-04-21 | 2021-07-20 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
US9265407B2 (en) | 2004-04-21 | 2016-02-23 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9055965B2 (en) | 2004-04-21 | 2015-06-16 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
US8858586B2 (en) | 2004-04-21 | 2014-10-14 | Acclarent, Inc. | Methods for enlarging ostia of paranasal sinuses |
US8864787B2 (en) | 2004-04-21 | 2014-10-21 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
US11202644B2 (en) | 2004-04-21 | 2021-12-21 | Acclarent, Inc. | Shapeable guide catheters and related methods |
US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
US11511090B2 (en) | 2004-04-21 | 2022-11-29 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US11529502B2 (en) | 2004-04-21 | 2022-12-20 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US10098652B2 (en) | 2004-04-21 | 2018-10-16 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US10034682B2 (en) | 2004-04-21 | 2018-07-31 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US9370649B2 (en) | 2004-04-21 | 2016-06-21 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US8961495B2 (en) | 2004-04-21 | 2015-02-24 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US9826999B2 (en) | 2004-04-21 | 2017-11-28 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
US8852143B2 (en) | 2004-04-21 | 2014-10-07 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US9649477B2 (en) | 2004-04-21 | 2017-05-16 | Acclarent, Inc. | Frontal sinus spacer |
US8945088B2 (en) | 2004-04-21 | 2015-02-03 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
US8905922B2 (en) | 2004-04-21 | 2014-12-09 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat |
US11589742B2 (en) | 2004-04-21 | 2023-02-28 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
US11864725B2 (en) | 2004-04-21 | 2024-01-09 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat |
US11957318B2 (en) | 2004-04-21 | 2024-04-16 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US9468362B2 (en) | 2004-04-21 | 2016-10-18 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US8870893B2 (en) | 2004-04-21 | 2014-10-28 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat |
US9039657B2 (en) | 2004-08-04 | 2015-05-26 | Acclarent, Inc. | Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US9039680B2 (en) | 2004-08-04 | 2015-05-26 | Acclarent, Inc. | Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US9084876B2 (en) | 2004-08-04 | 2015-07-21 | Acclarent, Inc. | Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders |
AU2017200564B2 (en) * | 2004-09-15 | 2019-03-28 | Optinose As | Nasal delivery devices |
EP2462972A2 (en) | 2004-09-15 | 2012-06-13 | Optinose AS | Nasal delivery devices |
EP2462973A3 (en) * | 2004-09-15 | 2013-12-11 | Optinose AS | Nasal delivery devices |
GB2449382B (en) * | 2004-09-15 | 2009-07-22 | Optinose As | Nasal delivery devices |
GB2418147A (en) * | 2004-09-15 | 2006-03-22 | Optinose As | Nasal delivery device with mouthpiece |
GB2449382A (en) * | 2004-09-15 | 2008-11-19 | Optinose As | Nasal delivery device with mouthpiece |
US8590530B2 (en) | 2004-09-15 | 2013-11-26 | Optinose As | Nasal delivery devices |
US10398859B2 (en) | 2004-09-15 | 2019-09-03 | Optinose As | Nasal delivery devices |
GB2429168A (en) * | 2004-09-15 | 2007-02-21 | Optinose As | Nasal delivery device with mouthpiece |
GB2429168B (en) * | 2004-09-15 | 2009-07-22 | Optinose As | Nasal delivery devices |
WO2006030210A3 (en) * | 2004-09-15 | 2006-05-11 | Optinose As | Nasal delivery devices |
GB2418147B (en) * | 2004-09-15 | 2008-03-05 | Optinose As | Nasal delivery devices |
EP2462972A3 (en) * | 2004-09-15 | 2013-08-28 | Optinose AS | Nasal delivery devices |
EP2462973A2 (en) | 2004-09-15 | 2012-06-13 | Optinose AS | Nasal delivery devices |
WO2006030210A2 (en) * | 2004-09-15 | 2006-03-23 | Optinose As | Nasal delivery devices |
US9308361B2 (en) | 2005-01-18 | 2016-04-12 | Acclarent, Inc. | Implantable devices and methods for treating sinusitis and other disorders |
CN101217992A (en) * | 2005-02-23 | 2008-07-09 | 奥普蒂诺斯公司 | Powder delivery devices |
CN103463716A (en) * | 2005-02-23 | 2013-12-25 | 奥普蒂诺斯公司 | Powder delivery devices |
WO2006090149A3 (en) * | 2005-02-23 | 2006-12-21 | Optinose As | Nasal delivery device |
WO2006090149A2 (en) * | 2005-02-23 | 2006-08-31 | Optinose As | Nasal delivery device |
US8899229B2 (en) | 2005-02-23 | 2014-12-02 | Optinose As | Powder delivery devices |
US11571531B2 (en) | 2005-02-23 | 2023-02-07 | OptiNose Inc. | Powder delivery devices |
US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
US10124154B2 (en) | 2005-06-10 | 2018-11-13 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
US10842978B2 (en) | 2005-06-10 | 2020-11-24 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
WO2007001650A1 (en) * | 2005-06-27 | 2007-01-04 | Kos Life Sciences, Inc. | Breath actuated drug delivery system |
WO2007001585A1 (en) * | 2005-06-27 | 2007-01-04 | Kos Life Sciences, Inc. | Breath actuated nasal drug delivery system |
US9999752B2 (en) | 2005-09-23 | 2018-06-19 | Acclarent, Inc. | Multi-conduit balloon catheter |
US8968269B2 (en) | 2005-09-23 | 2015-03-03 | Acclarent, Inc. | Multi-conduit balloon catheter |
US9050440B2 (en) | 2005-09-23 | 2015-06-09 | Acclarent, Inc. | Multi-conduit balloon catheter |
US10639457B2 (en) | 2005-09-23 | 2020-05-05 | Acclarent, Inc. | Multi-conduit balloon catheter |
US8397717B2 (en) | 2005-10-28 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Inhaler with mouthpiece having a microbiological protective function |
US9604017B2 (en) | 2005-11-15 | 2017-03-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Needle for piercing a powder capsule for inhalation |
US8006698B2 (en) | 2006-01-09 | 2011-08-30 | Pari Gmbh Spezialisten Fuer Effektive Inhalation | Aerosol therapy device |
EP3546000A1 (en) | 2006-01-19 | 2019-10-02 | Optinose AS | Nasal administration |
US10478574B2 (en) | 2006-01-19 | 2019-11-19 | Optinose As | Nasal administration |
WO2007093791A3 (en) * | 2006-02-14 | 2007-11-01 | Optinose As | Delivery device and method |
WO2007093791A2 (en) * | 2006-02-14 | 2007-08-23 | Optinose As | Delivery device and method |
EP1988953B1 (en) * | 2006-02-14 | 2017-07-19 | Optinose AS | Delivery device |
US10124132B2 (en) | 2006-03-06 | 2018-11-13 | Optinose As | Nasal delivery |
GB2435835B (en) * | 2006-03-06 | 2011-04-20 | Optinose As | Nasal delivery |
GB2435835A (en) * | 2006-03-06 | 2007-09-12 | Optinose As | Nosepiece for nasal delivery device |
WO2007102089A2 (en) | 2006-03-06 | 2007-09-13 | Optinose As | Nasal delivery |
US9272104B2 (en) | 2006-03-23 | 2016-03-01 | Optinose As | Nasal delivery |
US10864334B2 (en) | 2006-03-23 | 2020-12-15 | Optinose As | Nasal delivery |
US7870856B2 (en) | 2006-04-11 | 2011-01-18 | Boehringer Ingelheim International Gmbh | Inhaler |
WO2007116002A1 (en) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Inhaler |
WO2007118801A1 (en) | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim International Gmbh | Inhaler |
EP2656867A2 (en) | 2006-04-11 | 2013-10-30 | Boehringer Ingelheim Pharma GmbH & Co. KG | Mouthpiece for an inhalator |
US8875701B2 (en) | 2006-04-11 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Inhaler |
US20210346621A1 (en) * | 2006-06-08 | 2021-11-11 | Optinose As | Intranasal administration |
US10112021B2 (en) | 2006-06-08 | 2018-10-30 | Optinose As | Intranasal administration |
WO2007141541A1 (en) * | 2006-06-08 | 2007-12-13 | Optinose As | Intranasal administration |
US10765829B2 (en) | 2006-07-25 | 2020-09-08 | Optinose As | Delivery of gases to the nasal airway |
US11690969B2 (en) | 2006-07-25 | 2023-07-04 | OptiNose Inc. | Delivery of gases to the nasal airway |
GB2440316A (en) * | 2006-07-25 | 2008-01-30 | Optinose As | Nasal inhaler with scrubber |
WO2008030837A1 (en) * | 2006-09-06 | 2008-03-13 | Abbott Respiratory Llc | Variable dose aerosol drug canister |
US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
US9179823B2 (en) | 2006-09-15 | 2015-11-10 | Acclarent, Inc. | Methods and devices for facilitating visualization in a surgical environment |
US9603506B2 (en) | 2006-09-15 | 2017-03-28 | Acclarent, Inc. | Methods and devices for facilitating visualization in a surgical environment |
US10716629B2 (en) | 2006-09-15 | 2020-07-21 | Acclarent, Inc. | Methods and devices for facilitating visualization in a surgical environment |
US9572480B2 (en) | 2006-09-15 | 2017-02-21 | Acclarent, Inc. | Methods and devices for facilitating visualization in a surgical environment |
GB2477223A (en) * | 2006-11-28 | 2011-07-27 | Optinose As | Nasal delivery system with a replaceable nosepiece unit |
GB2453389B (en) * | 2006-11-28 | 2011-07-06 | Optinose As | Nasal delivery system with replaceable nosepiece unit |
US10639437B2 (en) | 2006-11-28 | 2020-05-05 | Optinose As | Delivery devices |
GB2470486A (en) * | 2006-11-28 | 2010-11-24 | Optinose As | Nasal delivery system with replaceable nosepiece unit |
US10525218B2 (en) | 2006-11-28 | 2020-01-07 | Optinose As | Nasal delivery devices |
EP2460555A2 (en) | 2006-11-28 | 2012-06-06 | Optinose AS | Nasal delivery device |
GB2453389A (en) * | 2006-11-28 | 2009-04-08 | Optinose As | Nasal delivery system with a replaceable nosepiece unit |
US10639438B2 (en) | 2006-11-28 | 2020-05-05 | Optinose As | Delivery devices |
US9038630B2 (en) | 2006-11-28 | 2015-05-26 | Optinose As | Delivery devices |
GB2477225A (en) * | 2006-11-28 | 2011-07-27 | Optinose As | Nasal delivery system with a replaceable nosepiece unit |
EP2460554A2 (en) | 2006-11-28 | 2012-06-06 | Optinose AS | Nasal delivery device |
GB2477224A (en) * | 2006-11-28 | 2011-07-27 | Optinose As | Nasal delivery system with a replaceable nosepiece unit |
GB2470486B (en) * | 2006-11-28 | 2011-08-31 | Optinose As | Nasal delivery devices |
US9010325B2 (en) | 2006-11-28 | 2015-04-21 | Optinose As | Nasal delivery devices |
GB2477225B (en) * | 2006-11-28 | 2012-04-04 | Optinose As | Nasal delivery devices |
WO2008091588A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
WO2008122791A2 (en) * | 2007-04-05 | 2008-10-16 | Optinose As | Nasal delivery |
EP3777939A2 (en) | 2007-04-05 | 2021-02-17 | Optinose AS | Nasal delivery |
US10076615B2 (en) | 2007-04-05 | 2018-09-18 | Optinose As | Nasal delivery |
GB2448183A (en) * | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
US10722667B2 (en) | 2007-04-05 | 2020-07-28 | Optinose As | Nasal administration |
US8875704B2 (en) | 2007-04-05 | 2014-11-04 | Optinose As | Nasal administration |
WO2008122795A3 (en) * | 2007-04-05 | 2009-06-11 | Optinose As | Nasal administration |
US8978647B2 (en) | 2007-04-05 | 2015-03-17 | Optinose, AS | Nasal delivery |
WO2008122795A2 (en) * | 2007-04-05 | 2008-10-16 | Optinose As | Nasal administration |
US9649456B2 (en) | 2007-04-05 | 2017-05-16 | Optinose As | Nasal administration |
WO2008122791A3 (en) * | 2007-04-05 | 2009-06-25 | Optinose As | Nasal delivery |
EP3777939A3 (en) * | 2007-04-05 | 2021-05-12 | Optinose AS | Nasal delivery |
US8347878B2 (en) | 2007-04-11 | 2013-01-08 | Pari GmbH Spezialisten für effektive Inhalation | Aerosol therapy device |
US9615775B2 (en) | 2007-04-30 | 2017-04-11 | Acclarent, Inc. | Methods and devices for ostium measurements |
US9463068B2 (en) | 2007-05-08 | 2016-10-11 | Acclarent, Inc. | Methods and devices for protecting nasal turbinates |
DE102007033860A1 (en) | 2007-07-20 | 2009-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Test arrangement for testing sealing between mouthpiece of inhaler and user's lips has channel for secondary air around user's lips with second flow measurement device |
DE102007036412A1 (en) | 2007-07-20 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tester |
US11083858B2 (en) | 2007-10-03 | 2021-08-10 | Optinose As | Nasal delivery devices |
US10252010B2 (en) | 2007-10-03 | 2019-04-09 | Optinose As | Nasal delivery devices |
US11602603B2 (en) | 2007-10-03 | 2023-03-14 | Optinose, Inc. | Nasal delivery devices |
US9067034B2 (en) | 2007-10-03 | 2015-06-30 | Optinose As | Nasal delivery devices |
WO2009044172A1 (en) | 2007-10-03 | 2009-04-09 | Optinose As | Nasal delivery devices |
DE102007052871A1 (en) | 2007-11-02 | 2009-05-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Capsule for receiving pharmaceutical drug formulations |
US10206821B2 (en) | 2007-12-20 | 2019-02-19 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
US11850120B2 (en) | 2007-12-20 | 2023-12-26 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
US11311419B2 (en) | 2007-12-20 | 2022-04-26 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
US9861793B2 (en) | 2008-03-10 | 2018-01-09 | Acclarent, Inc. | Corewire design and construction for medical devices |
US10271719B2 (en) | 2008-07-30 | 2019-04-30 | Acclarent, Inc. | Paranasal ostium finder devices and methods |
US11116392B2 (en) | 2008-07-30 | 2021-09-14 | Acclarent, Inc. | Paranasal ostium finder devices and methods |
US9750401B2 (en) | 2008-07-30 | 2017-09-05 | Acclarent, Inc. | Paranasal ostium finder devices and methods |
US8979888B2 (en) | 2008-07-30 | 2015-03-17 | Acclarent, Inc. | Paranasal ostium finder devices and methods |
DE202008015493U1 (en) | 2008-11-21 | 2009-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | folding |
US11207087B2 (en) | 2009-03-20 | 2021-12-28 | Acclarent, Inc. | Guide system with suction |
US10524814B2 (en) | 2009-03-20 | 2020-01-07 | Acclarent, Inc. | Guide system with suction |
US9636258B2 (en) | 2009-03-31 | 2017-05-02 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
US9072626B2 (en) | 2009-03-31 | 2015-07-07 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
US10376416B2 (en) | 2009-03-31 | 2019-08-13 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
WO2011055068A1 (en) | 2009-11-03 | 2011-05-12 | Valois Sas | Fluid material-dispensing device |
FR2952042A1 (en) * | 2009-11-03 | 2011-05-06 | Valois Sas | DEVICE FOR DISPENSING FLUID PRODUCT. |
CN102770174A (en) * | 2009-11-03 | 2012-11-07 | 瓦卢瓦有限合伙公司 | Fluid material-dispensing device |
US9186471B2 (en) | 2009-11-03 | 2015-11-17 | Aptar France Sas | Fluid material-dispensing device |
FR2960423A1 (en) * | 2010-05-27 | 2011-12-02 | Laurent Michel Marie Charroin | Device for administrating liquid charged or not charged with paranasal sinus substances, has mechanical unit generating movement of fluid directed toward otorhinolaryngology sphere in fluid supply circuit |
WO2012035427A1 (en) | 2010-09-14 | 2012-03-22 | Optinose As | Nasal delivery |
US11291626B2 (en) | 2010-09-14 | 2022-04-05 | Optinose As | Nasal delivery of oxytocin |
US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
WO2012123819A1 (en) | 2011-03-15 | 2012-09-20 | Optinose As Et Al | Nasal delivery |
US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
CN104428025A (en) * | 2012-02-24 | 2015-03-18 | 奥普蒂诺斯公司 | Nasal delivery devices |
US11033696B2 (en) | 2012-02-24 | 2021-06-15 | Optinose As | Nasal delivery devices |
WO2013124492A1 (en) | 2012-02-24 | 2013-08-29 | Optinose As | Nasal delivery devices |
US10179216B2 (en) | 2012-02-24 | 2019-01-15 | Optinose As | Nasal delivery devices |
WO2013124493A1 (en) | 2012-02-24 | 2013-08-29 | Optinose As | Nasal delivery devices |
EP3281664A1 (en) | 2012-02-24 | 2018-02-14 | Optinose AS | Nasal delivery devices |
US10300229B2 (en) | 2012-02-24 | 2019-05-28 | Optinose As | Nasal delivery devices |
EP3799909A1 (en) | 2012-02-24 | 2021-04-07 | Optinose AS | Nasal delivery devices |
US10076614B2 (en) | 2012-02-24 | 2018-09-18 | Optinose As | Nasal delivery devices |
WO2013124491A1 (en) | 2012-02-24 | 2013-08-29 | Optinose As | Nasal delivery devices |
US10524869B2 (en) | 2013-03-15 | 2020-01-07 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US9629684B2 (en) | 2013-03-15 | 2017-04-25 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US9433437B2 (en) | 2013-03-15 | 2016-09-06 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
WO2014155192A2 (en) | 2013-03-26 | 2014-10-02 | Optinose As | Nasal administration |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
EP4062939A1 (en) | 2013-03-26 | 2022-09-28 | Optinose AS | Nasal administration |
USD773644S1 (en) | 2013-05-23 | 2016-12-06 | Optinose As | Nosepiece unit |
USD759805S1 (en) | 2013-05-23 | 2016-06-21 | Optinose As | Nosepiece unit |
USD809128S1 (en) | 2013-05-23 | 2018-01-30 | Optinose As | Nosepiece unit |
USD761951S1 (en) | 2013-05-23 | 2016-07-19 | Optinose As | Nosepiece unit |
EP4233950A1 (en) | 2014-06-25 | 2023-08-30 | Optinose, Inc. | Nasal administration |
US11052204B2 (en) | 2014-11-19 | 2021-07-06 | Optinose As | Intranasal administration |
US11707586B2 (en) | 2014-11-19 | 2023-07-25 | OptiNose Inc. | Intranasal administration |
US11730904B2 (en) | 2014-11-19 | 2023-08-22 | Optinose, Inc. | Intranasal administration |
US10940277B2 (en) | 2014-11-19 | 2021-03-09 | Optinose As | Intranasal administration |
WO2023135237A1 (en) | 2022-01-14 | 2023-07-20 | Cybin Irl Limited | Tryptamine compositions and methods |
WO2023156450A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
WO2023156453A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
WO2023186963A1 (en) | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1161274B1 (en) | Nasal delivery device | |
US20230381097A1 (en) | Nasal delivery | |
US20220347092A1 (en) | Nasal delivery | |
RU2258538C2 (en) | Feeding apparatus for nose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00804558.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09700532 Country of ref document: US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 144988 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2364009 Country of ref document: CA Ref document number: 2364009 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/01011/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/008849 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 602333 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017011177 Country of ref document: KR Ref document number: 2001/02563 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 28227/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 514442 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000906570 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017011177 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000906570 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 28227/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000906570 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017011177 Country of ref document: KR |